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1.4 Abbreviations: 
Arg-1 arginase-1 
B7-H1 B7-homologue family member-1 
BBB  Blood brain barrier 
BLI biolumenscence imaging  
BM bone marrow 
BM-IMC   bone marrow generated immature myeloid cell 
BM-MDSC  bone marrow generated myeloid derived suppressor cells 
BM-DC  bone marrow generated dendritic cell 
BSA  Bovine Serum Albumin 
C/EBP-b  CAAT/enhancer binding protein-beta 
CD  Cluster of Differentiation 
CFA  Complete Freunds Adjuvant 
CFSE  carboxyfluorescein diacetate succinimidyl ester 
CLR C-Type Lectin receptor 
CNS  central nervous system 
CpG Cytosine phosphate guanine 
DC  dendritic cells 
DNA deoxyribosenucleic acid 
dsDNA double stranded DNA 
dsRNA double stranded RNA 
EAE  Experimental Autoimmune Encephalomyelitis 
ELISA Enzyme linked immunoabsorbant assay 
FACS flow cytometry 
FLT-3L  Fms like tyrosine kinase 3 ligand 
GM-CSF  granulocyte macrophage colony stimulating factor 
i.c. intracranially 
i.p. intraperitoneally 
i.v. intravenously 
IFN-b  Interferon beta 
IFN-g  Interferon gamma 
IL  interleukin 
IMC  Immature myeloid cell 
iNOS inducible nitric oxide synthase 
Iono  Ionomycin 
ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunorecptor tyrosine-based inhibition motif 
Jak Janus kinase 
LPS  Lipopolysaccharide  
Luc+ Luciferase positive 
MBP myelin basic protein 
MDSC  myeloid derived suppressor cells 
MHC Major Histocomptability complex 
MLR mixed lymphocyte reaction 
MOG myelin oligodendricyte protein 
MS  Multiple Sclerosis 
MyD88 Myeloid differentiation factor 88 
NF-kB nuclear factor kappa light chain enhancer of activated B cells 
NO  Nitric oxide  
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OVA ovalbumin  
PAMP Pathogen associated molecular pattern 
PD-1 Programmed Death Receptor -1 
PMA  phorbol 12-myristate 13-acetate 
Poly (I:C)  Polyinosinic:polycytidylic acid 
PRR Pathogen recognition receptor 
RBC red blood cell 
RNA ribosenucleic acid 
ROS Reactive oxygen species 
s.c. subcutaneously 
SEB staphylococcus enterotoxin subunit B 
STAT Signal Transducer and Activator of Transcription 
TCR T-cell receptor 
Teff T effector cell 
TLR Toll-like receptor 
Th1 T helper cells (Type 1) 
Th2 T helper cells (Type 2) 
Th17 T helper cells (Type 17) 
Tr1 Regulatory T cells (Type I) 
Treg Regulatory T cell 
WT  wildtype  
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1.6 Summary 
 
Autoimmune diseases, unwanted overshooting immune responses against self 
antigens, are due to an imbalance in immunity and tolerance. Although negatively 
impacting cancer prognosis, myeloid derived suppressor cells (MDSC), with their 
potent suppressive capabilities, might be applicable in a more beneficial light when 
applied in to autoimmunity.  As previous shown MDSC have protective roles in 
Experimental Autoimmune Encephalomyelitis (EAE) (Zhu et al., 2007), the 
established inducible mouse model for the autoimmune disease multiple sclerosis 
(MS).  This decrease in disease severity indicates in vitro generated immature 
myeloid cells (IMC) from bone marrow (BM) as precursors of MDSC are promising 
candidates for cellular therapy. Important to any cellular therapy by adoptive transfer, 
the major questions regarding BM-IMC efficacy was addressed within the thesis.  
This thesis attempts to elucidate how BM-IMC operate in EAE. This thesis defines 
the factors within the autoimmune microenvironment that lead to the activation of 
BM-MDSC, where BM-IMC home once delivered in vivo, and the protective 
mechanisms BM-IMC employ.    
 
To emulate BM cells when they first enter circulation through the blood, BM-IMC 
were injected intravenously (i.v.). BM-IMC are protective with no regard to the 
various routes delivered (i.v., i.p.).  They protect to a lesser extent when pre-activated 
before injection. BM-IMC suppress by causing a delay and/or by decreasing the 
severity of the disease via a mechanism yet determined.   
 
To understand the migration pattern of BM-IMC after i.v. injection, in vivo kinetics 
experiments employing bioluminescence imaging were performed.  This techinique 
allows for whole in vivo mouse imaging daily, allowing the tracking of cell migration 
over days within a single mouse.  During steady-state, BM-IMC circulate and appear 
to accumulate in the spleen by day 4 after injection, whereas they alternatively home 
to inflammatory sites (immunization site), draining lymph nodes, and the spleen 
within mice with low grade EAE.  Visualization of CM-DiI-labelled BM-IMC by 
fluorescence microscopy could locate BM-IMC injected cells outside the white pulp, 
as they were co-localizing in the regions stained with CD169 or outside, but not 
within the follicles of spleens on day 4.  Consistant with these findings, the attempt to 
analyze the phenotype of these cells by flow cytometry was problematic as these cells 
seem to adhere strongly to collagen also indicating the cells are located in the 
collagenous area of the marginal zone and the red pulp. 
 
To determine factors influencing MDSC activation, we utilized different stimuli 
through a high throughput method detecting release of nitric oxide (NO).  Extracts 
from yeast, fungi, and bacteria were observed to activate MDSC to produce nitric 
oxide. Surprisingly, material mimicking viral DNA (CpG) and RNA (poly I:C), and 
several self glycolipids, could not activate the MDSC to produce NO. Upon attempts 
to understand synergistic effects between microbial pathogens and host cytokines, 
IFN-g was determined to boost the signal of pathogen stimuli, whereas IL-17, another 
cytokine which causes pathology during EAE, and IFN-b, a drug used in therapy to 
treat MS, did not cause any additional effects.  Activation of BM-MDSC was 
determined by the microbial pathogens components LPS, curdlan, and zymosan, to 
induce upregulation of B7-H1 on the cell surface.  BM-MDSC did not increase any 
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co-stimulatory markers, such as CD40, CD80, CD86, CD70, or the co-inhibitory 
marker, PD-L2. On day 1 after EAE induction, endogenous MDSC populations when 
stimulated showed an increase in B7-H1 expression and a downregulation of CD80.  
After further analysis, these cells were concluded to be mostly granulocytic cells (Ly-
6G+).  As the B7-H1 ligand PD-1 is upregulated in chronic diseases and correlates to 
an exhausted phenotype, the PD-1 : B7-H1 interaction was a good candidate for the 
mechanism our cells may employ for their suppressive capacity. To investigate this 
interaction, fixed BM-IMC deficient in B7-H1 were incubated with restimulated 
memory T cells.  BM-IMC deficient in B7-H1 resulted in a significant loss of T cell 
suppression, as compared to the wildtype control BM-IMC.  To assess this interaction 
in vivo, we injected wildtype (WT) and B7-H1-/- BM-IMC into mice followed by 
induction of EAE to assess whether B7-H1 mediated this suppression.  The lack of 
B7-H1 did not alter their suppressive capacity under these conditions, contrary to 
other findings which have described this interaction to be important in their 
suppressive capacity when administered post EAE induction (Ioannou et al., 2012).   
Interestingly, EAE mice pre-treated with BM-IMC had similar amounts of cytokine 
production in the CNS after restimulation.  Spleens from BM-IMC injected mice had 
increased amounts of Arg-1 suggesting suppression is via oxidation or recruitment by 
soluble mediators may lead to this protection.  We speculate this may inhibit T cell 
reactivation in the CNS.      
 
We conclude that MDSC, upon further testing in human, might be a potential 
candidate as a suppressive cellular therapy for MS.  This thesis provides insight into 
the ability of MDSC to suppress the severity of EAE.  The suppressive capacity of 
MDSC is not altered by the current therapy, IFN-b, therefore it may be possible to 
utilize in a combinational therapy.  Our findings also demonstrate that if given as a 
preventive cellular therapy, the cells would home to the spleen and suppress the 
activated T cells through direct release of NO, but not B7-H1.  Further roles of PD-1 
in EAE protection may need to be elucidated.   
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1.7 Zusammenfassung 
 
Autoimmunerkrankungen, unerwünschte, überschießende Immunantworten gegen 
Selbstantigene, resultieren aus einem Ungleichgewicht von Immunität und Toleranz. 
Obwohl sie einen negativen Einfluss auf Tumorerkrankungen haben, könnten 
Myeloide Suppressorzellen (MDSC) durch ihre potenten immunsuppressiven 
Eigenschaften, in einem besseren Licht bei Anwendung gegen 
Autoimmunerkrankungen erscheinen. Wie zuvor gezeigt, können MDSC eine 
protektive Rolle bei der Experimentellen Autoimmunenzephalomyelitis (EAE) 
entfalten, dem etablierten induzierbaren Mausmodel für die Autoimmunerkrankung 
Multiple Sklerose (MS). Die Verminderung der Erkrankungssymptome deutet darauf 
hin, dass in vitro aus Knochenmark (BM) generierte unreife myeloide Zellen (IMC) 
als Vorläufer von MDSC viel versprechende Kandidaten für eine Zelltherapie 
darstellen. Da für jede Art der Zelltherapie die Effektivität der transferierten Zellen 
eine entscheidende Rolle spielt, sollte in dieser Arbeit die Funktionalität von BM-
IMC untersucht werden. Diese Dissertation erarbeitet wie BM-IMC bei der EAE 
funktionieren. Die Arbeit versucht die Faktoren innerhalb der Autoimmun-
Mikroumgebung zu definieren, welche zur BM-MDSC Aktivierung führen, wohin 
applizierte BM-IMC in vivo wandern und welche protektiven Mechanismen BM-IMC 
anwenden. 
 
Um nachzubilden, wie BM Zellen bei ihrem Eintritt in das Blut sich in der Zirkulation 
verhalten, wurden BM-IMC intravenös injiziert. Die injizierten gemischten BM-IMC 
verhielten sich protektiv, unabhängig von der Art der Injektion (i.v., i.p.). Sie sind 
jedoch weniger protektiv, wenn sie voraktiviert injiziert wurden. BM-IMC 
supprimieren auf eine Weise, dass sie eine Verzögerung und/oder Verminderung der 
Erkrankungssymptome bewirken, wobei die dafür zugrunde liegenden Mechanismen 
noch nicht definiert sind.  
 
Um die Wanderungsmuster der BM-IMC nach i.v. Injektion zu verstehen, wurden in 
vivo Kinetikexperimente mittels der Biolumineszenz-Darstellung durchgeführt. Diese 
Technik erlaubt eine tägliche Betrachtung der gesamten lebenden Maus, so dass die 
Zell-Wanderungsmuster über Tage in derselben Maus aufgezeichnet werden können. 
Unter homöostatischen Bedingungen zirkulieren BM-IMC bis sie nach 4 Tagen in der 
Milz akkumulieren, wogegen sie alternativ zu Entzündungsherden wandern 
(Immunisierungssstelle), in Lymphknoten und Milz in Mäusen mit milden EAE 
Symptomen. Deren Lokalisierung konnte durch Fluoreszenzmikroskopie von CM-
DiI-markierten BM-IMC in der roten Pulpa der Milz an Tag 4 lokalisiert werden. In 
Übereinstimmung mit diesem Befund, waren durchflusszytometrische Phänotyp-
Analysen problematisch, da die Zellen fest an Kollagenfasern gebunden schienen, was 
als weiterer Hinweis auf ihre Kollagenbindung dienen kann.  
 
Um Faktoren zur Aktivierung zu bestimmen, wurden verschiedene MDSC Stimuli 
benutzt und deren Freisetzung von Stickstoffmonoxid (NO) mittels einer 
Hochdurchsatzmethode bestimmt. Es konnte nachgewiesen werden, dass Extrakte aus 
Hefen, Pilzen und Bakterien MDSC aktivieren und zur NO Produktion führen. 
Überraschenderweise konnten DNS- (CpG) oder RNS-Bestandteile (Poly I:C) mit 
viralen Charakteristika oder verschiedenen Selbst-Glykolipide keine NO Freisetzung 
hervorrufen. Darüber hinaus konnte für das Zytokin IFN-g eine wichtige verstärkende 
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Rolle gezeigt werden, wobei ein anderes bei der EAE-Pathogenese beteiligte 
beteiligtes Zytokin, IL-17, und auch IFN-b, eine Substanz zur Therapie der MS, 
keinerlei Effekte zeigten. Untersuchungen nach MDSC-Aktivierung mit den 
mikrobiellen Komponenten LPS, Curdlan und Zymosan zeigten eine Hochregulation 
des B7-H1 Moleküls auf der Zelloberfläche. Andere kostimulatorische Marker, wie 
CD40, CD80, CD86, CD70 oder der inhibitorische Marker PD-L2 nahmen nicht zu. 
Einen Tag nach EAE-Induktion exprimierten auch die endogene MDSC Populationen 
nach Stimulation eine erhöhte B7-H1 und eine erniedrigte CD80 Expression. Nach 
weiterer Analyse konnten diese Zellen überwiegend als granulozytär (Ly-6G+) 
eingestuft werden. Da der B7-H1-Ligand PD-1 bei chronischen Erkrankungen 
hochreguliert wird, und mit einem verbrauchten Phänotyp korreliert, sollte die PD-
1:B7-H1 Interaktion als guter Kandidat für den Suppressionsmechanismus untersucht 
werden. Fixierte B7-H1-defiziente BM-IMC wurden auf ihre Suppressorfunktion auf 
Gedächtnis-T-Zellen getestet. B7-H1-defiziente IMC zeigten eine signifikant 
niedrigere Suppression, im Vergleich zu Wildtyp BM-IMC. Um diese Interaktion in 
vivo zu untersuchen, wurden Wildtyp- oder B7-H1-defiziente BM-IMC in Mäuse 
injiziert und danach EAE induziert um auch hier eine B7-H1-vermittelte Suppression 
nachzuweisen. Die Abwesenheit von B7-H1 veränderte jedoch die suppressiven 
Eigenschaften unter diesen Bedingungen nicht, im Gegensatz zu anderen 
beschriebenen Befunden bei denen eine wichtige suppresive Rolle bei Injektion nach 
EAE-Induktion beschrieben wurde. Interessanterweise zeigten Mäuse, welche mit 
BM-IMC vorbehandelt wurden, eine vergleichbare Zytokinfreisetzung im ZNS nach 
Restimulation. Milzen zeigten nach BM-IMC Injektion auch erhöhte Mengen 
Arginase-1 könnte dies auf eine Suppression durch oxidative Mediatoren hindeuten. 
Man kann also annehmen, dass so eine Reaktivierung der T Zellen im ZNS verhindert 
wird.  
 
Zusammenfassend stellen MDSC, nach weiteren Tests im Menschen, einen 
möglichen Kandidaten zur suppresiven Zelltherapie bei MS dar. Diese Arbeit erlaubt 
Einblicke in die Fähigkeit von MDSC die EAE zu unterdrücken. Die suppressive 
Fähigkeit von MDSC ist durch die gegenwärtige IFN-b Therapie unbeeinflusst, so 
dass eine kombinatorische Therapie möglich wäre. Die Ergebnisse zeigen auch, dass 
bei präventiver Gabe eine Migration in die Milz zu beobachten ist, wo Suppression 
der aktivierten T Zellen durch NO Freisetzung, jedoch nicht B7-H1, stattfindet. Um 
eine weitere Beteiligung von PD-1 bei der EAE abzuklären bedarf es zusätzlicher 
Analysen.  
 
 
Translation performed by Dr. Manfred Lutz and Anja Döhler 
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2 INTRODUCTION 
2.1 Immune Responses 
Immunology is the study of the balance between tolerance and activation of immune 
cells in response to self and foreign antigens.  As the human body consists of more 
than 90% cells of non-human origin (Turnbaugh et al., 2007) mostly consisting of 
commensal bacteria, understanding this balance is important.  Physical barriers, such 
as the gastrointestinal and respiratory tracts and skin, and soluble mediators, like anti-
microbial substances and defensins, provide primary defenses by keeping pathogens 
out of the body (Abbas AK, 2010).  The immune system fights pathogens managing 
to surpassed the physical barriers (Abbas AK, 2010).  The immune system can 
regulate self tissues in cases of uncontrollable growth (tumors and cancer) and 
mediates removal of damaged or dying tissues (Abbas AK, 2010).  The immune 
system consists of both innate and adaptive immune cells, which generally play 
different roles in fighting pathogens, but work in concert through communication 
(Abbas AK, 2010).  The function of the immune system in regulating tolerance and 
defending from pathogens is a constant process.  Although there is much functional 
overlap within the immune system, dysfunction of immune cells shows major effects.  
An example of the problems resulting from disregulation of the immune system is the 
appearance of autoimmune diseases (Abbas AK, 2010).  Autoimmune diseases, 
activated by various triggers both genetic and environmental in nature, are induced by 
an overshooting response of the immune system against self tissues.  This generally 
leads to dehabilitatation of the individual.   Autoimmunity will be discussed in greater 
detail later in the thesis. 
2.1.1 Innate Immunity 
The innate immune cells and soluble factors, i.e., complement, are the first responders 
(Abbas AK, 2010).  Innate immunity consists of macrophages, dendritic cells (DC), 
monocytes, granulocytes and NK cells that recognize a limited number of conserved 
structures of repeating components of pathogens, called pattern associated molecular 
patterns (PAMP), by using pattern recognition receptors (PRR) upon their surface.  
PRR are specifically programmed within the cell’s germline DNA (Abbas AK, 2010).  
PRR consist of many different classes of receptors, such as toll-like receptors (TLR), 
c-type lectins receptor (CLR), NOD-like receptors, and RIG-I like receptors, which 
together recognize different types of antigens and lead to various further immune 
responses (Abbas AK, 2010).  Each PRR recognizes a specific PAMP, i.e., bacterial 
cell walls, leading to different subsequent signalling resulting in activation (Abbas 
AK, 2010).  This signalling activates the innate immunity to upregulate other 
molecules or the release of proinflammatory cytokines to assist in furthering the 
immune response through activating and directing the adaptive immunity (Abbas AK, 
2010). 
 
Dendritic cell-associated C-type lectin-1 (Dectin-1), a CLR recognizing carbohydrate 
antigen, is expressed predominately on myeloid cells, but can also be expressed on 
other immune cells (Brown and Gordon, 2001).  Dectin-1 functions by first 
recognizing beta-glucans (repeating glucose polysaccharides linked by glycosidic 
bonds) on fungal and yeast pathogens, such as curdlan and zymosan, respectively 
(Brown and Gordon, 2001), or other undetermined molecular patterns on other 
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pathogens like mycobacteria (Rothfuchs et al., 2007; Yadav and Schorey, 2006).  
Once interacting with the beta-glucan, Dectin-1 signals through Syk-CARD9 for 
Th17 responses (LeibundGut-Landmann et al., 2007).  Curdlan signalling with GM-
CSF leads to synergic signals in DC, thereby inducing increased costimulatory 
molecules and more cytokine production, including IL-6 and IL-12p70 (Min et al., 
2012).  Other glycan receptors, like galactin-1, have been reported to support more 
tolerogenic signals into DC (Ilarregui et al., 2009). 
 
Possibly the most well known family of PRR are the TLRs (Abbas AK, 2010).  These 
receptors recognize specific PAMPs from a variety of sources, including bacterial, i.e., 
gram negative cell walls, such as lipopolysachharide (LPS), viral, i.e., viruses 
encoded by double stranded RNA (dsRNA), also mimicked by poly (I:C), or double 
straded DNA (dsDNA), mimicked by cysteine and guanine rich DNA regions (CpG), 
in nature (Abbas AK, 2010).  Of these discovered 12 TLR, the majority signal via a 
common adaptor protein myeloid differentiation factor-88 (MyD88).  Exceptions to 
MyD88 signalling by signalling alternatively through the TRIF dependent pathway 
include TLR3 and TLR4 (Akira et al., 2001).  TLR are typically located where the 
corresponding type of pathogen they detect are mostly located.  Bacterial components, 
e.g. LPS, signal through the extracellular TLR 2/4, whereas the intracellular 
pathogens, e.g. viruses, trigger through TLR 3, TLR 7, TLR 8, TLR 9, which are 
found in endosomes (Abbas AK, 2010).  Signalling through TLR can further activate 
the cell to regulate other receptors, costimulatory/coinhibitory molecules, or cytokines, 
which then control effector functions of the adaptive immunity (Abbas AK, 2010). 
 
The innate immunty is important in several ways:  Phagocytosing, otherwise known 
as the engulfment of particulate antigens (e.g. microbes), and the clearing dead tissue 
and debris through “eat-me” receptors and the sampling the soluble environment 
through uptake of liquid antigens, termed pinocytosis (Abbas AK, 2010). Ingestion of 
pathogens or damaged cell tissues are digested in the lysosomes into small proteins 
and subsequently loaded as peptides into major histocompatability complexes (MHC) 
(Abbas AK, 2010). MHC, classified into class I and II, are based on the length of the 
peptide which fits into its groove and the location, i.e., extracellular vs intracellular 
(Abbas AK, 2010) of the pathogen supplying these peptides.  The presenting of the 
peptide through MHC molecules to the scanning T cells is termed antigen 
presentation (Abbas AK, 2010).  The recognition of the peptide-MHC complex occurs 
by the T cell receptor (TCR) of the T cell (Abbas AK, 2010).  The MHC I molecule 
presents smaller peptides, 9-mers, usually of intracellular origin, which are recognized 
by CD8 cells, while the MHC II presents 15-mer peptides usually of extracellular 
origin to CD4 T cells (Abbas AK, 2010). As T cells recognize proteins, this immune 
response generated is peptide-based, but innate cells are not limited to this source of 
antigen and can also load glycolipids upon another presenting molecules, called CD1d, 
for presentation to NKT cells (Abbas AK, 2010).  The presentation of antigen delivers 
signals into the adaptive immune cell activating it (Abbas AK, 2010).  
2.1.2 Adaptive Immunity 
Adaptive responses work in concert with the innate immune responses, but have a 
different mode of response.  As its name implies, the process is adaptive and slower to 
mount, but it does support memory responses (Abbas AK, 2010).  Innate immunity 
primes the adaptive immune responses and directs the effector actions of the adaptive 
immunity. The two major players in adaptive immunity are of the lymphocyte family: 
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T lymphocytes (T cells) and B lymphocytes (B cells) (Abbas AK, 2010).  The T and 
B cells are considered adaptive because their T cell receptor or B cell receptor, 
respectively, changes during the course of infection to “adapt” through selection for 
cells that have better ability to recognize specific pathogens (Abbas AK, 2010).  
 
 
Figure I.1 Depiction of 3-step APC-T cell interaction for T cell activation. Signal 1: the MHC-
peptide-TCR (grey, center) interaction gives the first positive signal into the T cell.  Signal 2: possible 
co-stimulation or co-inhibitory signals (pink, top), gives second activation signal into T cell.  Signal 3: 
The release of cytokines by the APC direct T cell polarization. Figure from (Pardoll, 2002). 
2.1.3 Immune Activation 
Dendritic cells (DC) recognize and process antigen from the tissue through 
phagocytosis (Abbas AK, 2010).  After migrating to the nearest draining lymphoid 
organ, this antigen is processed and presented. Once the DC reaches the lymphoid 
organ, it moves into the white pulp, where it interacts with T cells (Abbas AK, 2010). 
Normally, immune cells are constantly scanning one another within the lymphoid 
organs.  This close contact and constant short cell-cell interaction provides a tonic 
TCR signal, otherwise known as survival signals (Romer et al., 2011).  Some suggest 
the length the time of this interaction decides which type of response is mounted 
(Corse et al., 2011).  
 
For activation of a specific subset of T cells, CD4 or T-helper cells, a specific series 
of events must occur.  Naive T cells migrate to secondary lymphoid organs where the 
association with required interaction partners is performed in a step-wise fashion 
(Abbas AK, 2010) (described in Figure I.1).  The first signal is through MHC 
presentation of peptide antigens to the TCR of T cells (Abbas AK, 2010; Pardoll, 
2002).  The second signal is delivered upon the co-stimulatory signal of the B7 
molecule (CD80 / CD86) interaction with CD28 (Abbas AK, 2010; Pardoll, 2002).  
Finally, the third signal given to the T cell is from cytokines released by the DC.  
These cytokines direct the T cell specific polarization (Abbas AK, 2010; Pardoll, 
2002) resulting in different effector phenotypes.  CD4 polarized cells have the 
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following classifications: Th1 cells which release IFN-g during times of inflammation 
and viral infection (Abbas AK, 2010); Th2 cells, which release IL4, IL-5, IL-13 
during parasitic infection and allergy (Abbas AK, 2010; Nurieva and Chung, 2010); 
Th17 cells which release IL-17, IL-21, IL-23 in times of wound healing and 
autoimmunity (Abbas AK, 2010; Nurieva and Chung, 2010); T regulatory cells 
(Tregs) which suppress in numerous ways, e.g. releasing TGF-b and IL-10 while 
involved in controlling immune responses (Abbas AK, 2010); and lastly, a newer 
defined population of T follicular cells involved in B cell maturation and 
autoimmunity (Nurieva and Chung, 2010).  Recently, it has been suggested the 
polarizations into different T-helper subsets may be induced by the strength and time 
of interaction of between the MHC and the TCR (Corse et al., 2011), caused by the 
maturation status of the DC (Pletinckx et al., 2011). 
 
 
Figure I.2 Polarization in CD4 T cells.  Naive T cells when activated are given signals by polarizing 
cytokines activating different transcription factors, which shape their “polarization” into different 
effector T helper cells. Figure modified from (Nurieva and Chung, 2010). 
 
Once they encounter a pathogen presented by the innate immune response, specific T 
cells will selectively proliferate (Abbas AK, 2010).  Due to different cytokine signals 
given to the T cell during priming, the T cell will polarize in a different manner, 
releasing different effector cytokines which best combat the type of protein antigen 
recognized (Abbas AK, 2010).  These T cells go through an expansion phase where 
increased amounts of effector T cells are generated to combat the infection.  A small 
portion of these cells will then futher differentiate into memory T cells, which can be 
recalled upon subsequent exposure to the same pathogen (Abbas AK, 2010).  
 
2.1.4 Spleen: Structure and Function 
The spleen functions as the largest filter of blood in the body (Kraal, 1992), acts as 
reservoir of monocytes (Swirski et al., 2009), and plays a vital role in systemic 
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immune responses as it functions as a secondary lymphoid organ.  The spleen is 
thought to play a essential role in the immune reaction against blood-borne pathogens.  
Due to its multi-functionality, organization of this organ is crucial.  The spleen is 
organized into stroma, the structural portion, and parenchyma, the cellular portion.  
The stroma consists of mostly reticular fibroblast cells which comprise the fibrous 
capsule of connective tissue surrounding the entire spleen and other splenic 
connective tissue, such as vessels.  The parenchyma is made up of the leukocyte 
population, consisting of T cells, B cells, macrophages, monocytes and other immune 
cells (Mebius and Kraal, 2005). 
 
The parenchyma of the spleen consists of two major zones: the red pulp and the white 
pulp (Mebius and Kraal, 2005).  The border between the red and white pulps is 
considered the marginal zone where macrophages normally reside (Mebius and Kraal, 
2005).  The blood enters the spleen through the chords of the red pulp, which must 
pass through the major filter of the spleen, by forcing the cells through slits formed by 
stress fibers and parallel endothelial cells to enter the sinuses (Mebius and Kraal, 
2005).  This is the primary site of turnover of dead cells, breakdown of cellular debris, 
and RBC degradation (Mebius and Kraal, 2005).  Tyrosine nitration has been shown 
to interfere with phosphorylation and targets the protein for degradation (Gow et al., 
1996).  To enter the white pulp, cells are required to undergo an active migration 
involving G-protein coupled receptors.  This G-protein coupled receptor migration 
into the white pulp can be inhibited by the administration of pertussis toxin (Cinalli et 
al., 2005), inducing an accumulation of T and B cells within the red pulp (Cyster and 
Goodnow, 1995).  Upon maturation DC through CCR7 undergo an active migration to 
enter the white pulp. The white pulp, where the adaptive immune responses occur, is 
further broken down into the T cell and B cell areas.  The interaction between DC and 
T cells occur in the T cell zone, where T cells become activated and move to the 
border of the T-B cell zone, where they can further interact with B cells (Abbas AK, 
2010).  The red pulp consists of mostly of plasmablasts, monocytes, and macrophages 
and is the main site for RBC degradation and iron recycling (Mebius and Kraal, 2005).  
It also has been reported that the red pulp is where memory CD8 cells may home 
(Bajenoff et al., 2010).  A reservoir of monocytes, located in the cords of the 
subcapsular red pulp, is released upon stress signals to injured tissue to initiate wound 
healing (Swirski et al., 2009).  During overexpression of TNF-a or chronic 
inflammation, the spleen structure changes dramatically, remodeling its organization 
and expanding to allow more infiltrating cells, and developing the formation of more 
germinal centers (Abbas AK, 2010). 
2.1.5 Adaptive Immune Development: Tolerance 
The thymus and the BM are considered the primary lymphoid organs and the sites of 
development of the T cell and B cells, respectively (Abbas AK, 2010).  The thymus is 
where the development of T cells pass through several check points before the cells 
can exit into the circulation (Abbas AK, 2010).  This process, termed central tolerance, 
is divided into positive and negative selection; both lead to the T cell’s ability to act 
against foreign pathogens and not against self (Abbas AK, 2010).  Immature T cells 
expressing both CD4 and CD8 enter the thymus and undergo positive selection 
(Abbas AK, 2010).  Positive selection occurs by the selection within the thymus 
which selects for the cells which bind to the self major histocompatibility complex 
(MHC) molecule with low avidity, therefore preventing harm to the host organism 
(Abbas AK, 2010).  This selection ensures only single positive CD4 or CD8 
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expression on the T cells, restricting them to interact with only MHC I or MHC II 
peptide presentation (Abbas AK, 2010).  During this step, the cells expressing high 
avidity will be eliminated (clonal deletion) by apoptosis or they will have their 
receptor altered (receptor editing) (Abbas AK, 2010).  Those which lack the 
interaction with the TCR die due to lack of signals (neglect), whereas the selected 
ones with the right avidity to self MHC receive positive survival signals to continue 
into the medullary chords, where they enter negative selection (Abbas AK, 2010).  
Located within the medullary chords of the thymus are cells with the particular ability 
to express self molecules found in every tissue which play a role in the selection 
process (Abbas AK, 2010).  Selection of T cells with the inability to bind these self 
antigens with high avidity is termed negative selection (Abbas AK, 2010). 
Unfortunately, this process of selection is not 100%, as some cells can escape and 
become autoreactive.  These self-reactive T cells can be pathogenic, leading to 
autoimmune diseases.  Once the T cells exit the thymus, they still have mechanisms of 
peripheral tolerance, which keep them in check (Abbas AK, 2010).  Peripheral 
tolerance mostly is based on the APC-T cell interaction.  This interaction is a very 
tightly controlled process which regulates the immune response against foreign 
antigens and protection of self (Abbas AK, 2010).  Peripheral tolerance mechanisms 
include anergy, deletion, and suppression (Abbas AK, 2010). 
2.1.6 Tolerance by Anergy 
When the immune interaction between T cells and DC occur, but lack the second 
signal, the cells become non-functional or anergic (Abbas AK, 2010).  Another way to 
induce anergy is through co-inhibitory signals, such as the B7-homologue-1 (B7-H1) 
interacting with programmed death receptor-1 (PD-1) or with cytotoxic T-lymphocyte 
antigen-4 (CTLA-4) on T cells (Abbas AK, 2010).  These inhibitory factors deliver 
signals into the T cell through the immunoreceptor tyrosine-based inhibition motif 
(ITIM) rather than the immunoreceptor tyrosine-based activation motif (ITAM).  
Therefore, instead of becoming activated, the cells fall into an anergic state (Abbas 
AK, 2010).  
2.1.7 Programmed  Death Receptor-1 and B7-family member homologue-1  
Freeman et al. (Freeman et al., 2006) have termed T cells with the loss of their 
effector function during chronic infections, such as HIV and LCMV, “exhausted.”  
The phenotype of “exhausted” cells is that they display an increase in programmed 
death receptor-1 (PD-1) expression, as well as have decreased effector functions, such 
as cytokine release, cytotoxic lysis, and proliferative capacity (Figure I.3) (Freeman et 
al., 2006). These cells during the course of infection are deleted as PD-1 makes them 
more susceptible to apoptosis mediated death (Bhadra et al., 2012). PD-1 has been 
reported to play a role not only in the periperal tolerance, but also has a role in 
positive selection during central tolerance (Nishimura et al., 2000). 
 
PD-1 expression was first discovered on dying cells, but unlike its name, it doesn’t 
trigger cell death, but rather anergy by triggering inhibitory signals into the cell 
(Ishida et al., 1992; Tsushima et al., 2007). After triggering PD-1, the cells increase 
motility (Fife et al., 2009), maybe explaining this anergy, by decreasing the 
opportunity for immune cell-cell interactions.  Interestingly, PD-1 is found on resting 
Tregs (Raimondi et al., 2006).  The interaction of PD-1 with its ligand B7-H1, also 
known as programmed death receptor ligand-1 (PD-L1), increases Tregs, but the 
mechanisms to do so are not clear. Immature DC have been described to have higher 
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expression of PD-1 compared to mature DC (Kuipers et al., 2006).  Also, expression 
of its ligand, B7-H1, on DC is regulated by factors regulating maturation (Liu et al., 
2007) through IRF-1, Erk, p38 signalling (Karakhanova et al., 2010; Lee et al., 2006).  
Further studies have shown PD-1 expression on DC regulate IL-6, MIP-a, IL-12, and 
TNF-a production (Pena-Cruz et al., 2010; Yao et al., 2009). 
Ligands for PD-1 are B7-H1, also referred to as PD-L1, and B7-DC, also known as 
PD-L2.  These ligands are differentially expressed on different cell types and at 
different times.  B7-H1 is constitutively expressed in immune restricted organs, such 
as the CNS, eyes, and placenta (Hori et al., 2006; Petroff et al., 2002).  The expression 
of B7-H1 is not restricted to these cell types, as B7-H1 can also be expressed on other 
non-hematopoetic cells and most immune cells, including T cells, B cells, monocytes, 
and DC (Freeman et al., 2000; Yamazaki et al., 2002).  The other ligand, PD-L2, 
expressed mostly on myeloid cells and a few other hematopoetic cells, is highly 
expressed by cells within the thymus, whereas B7-H1 expression is mainly localized 
to the spleen (Liang et al., 2003).  In various cell types, B7-H1 has been described to 
be upregulated upon IFN-g stimulation (Lee et al., 2005; Liu et al., 2007).  B7-H1 can 
also interact with other B7 family members, such as CD80 (Butte et al., 2007).  This 
interaction overlaps the binding of CD80 with PD-1 and CTLA-4, which still results 
in inhibitory signals into both cells (Butte et al., 2007). 
 
 
Figure I.3 The exhausted phenotype of T cells includes an increase of PD-1 expression and a 
decrease of proliferation and proinflammatory cytokines.  Figure from (Freeman et al., 2006). 
 
During experimental autoimmune encephalomyelitis (EAE), a mouse model for the 
study of the autoimmune disease multiple sclerosis (MS) discussed in more detail 
later in this thesis, B7-H1 and PD-1 expression increases in the CNS increasing with 
time correlating with disease score, with the peak between weeks 2 and 3 (Salama et 
al., 2003).  Mice lacking B7-H1 and PD-1 genes present with more severe symptoms 
(Ortler et al., 2008).  Experiments performed with blocking B7-H1 and PD-1 show 
similar importance of these genes in protecting against EAE (Salama et al., 2003) 
(Zhu et al., 2006).  Interestingly, it is claimed that during EAE, B7-H1 can selectively 
suppress Th1 responses better than Th17 responses, in vivo (Schreiner et al., 2008). 
 
2.1.8 Suppression as a Mode of Tolerance 
Suppression is another important tolerance mechanism (Abbas AK, 2010).  Various 
mechanisms to inhibit the immune response through the use of cytokines and the 
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deprevation of required amino acids are employed by different cell types (Abbas AK, 
2010).  One mechanism of suppression is via the famous Tregs.  Although immune 
suppression is not a new topic, as originally proposed in 1970s (Gershon, 1975), 
Tregs, once questionable to the scientific community due to the inability to clearly 
define their exact function, were only recognized recently by the research community 
as important components of the immune system.  Phenotypically, they are 
characterized by their expression of CD4, interleukin-2 receptor-alpha (CD25), and 
forkhead-winged-helix transcription factor (Foxp3) (Sakaguchi et al., 2010).  There is 
a long list of various ways in which these cells can regulate the immune system 
(Sakaguchi et al., 2010), most commonly reported is their ability to release TGF-b.  
Their important role in regulating immune responses, even during steady-state, is seen 
in scurfy mice.  Scurfy mice, mice containing a mutation in the FoxP3 gene (Bennett 
et al., 2001), lack regulation by self-reactive T cells and as a consequence have severe 
autoimmune diseases. In humans, this mutation causes a condition termed IPEX 
(immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome), 
leading to, as the name implies, very severe autoimmune diseases (Sakaguchi et al., 
2010).  Another suppressive cell type is the type 1 T regulatory (Tr1) cells which are 
most notably the producers of IL-10 (Roncarolo et al., 2006). 
 
Myeloid cell-based suppression has been described in various cases by triggering of 
various receptors, such as the scavenger receptors, glutocorticoid receptor, and 
cytokine receptors, as well as storage of low-oxidized lipids (Abbas AK, 2010).  
2.2 Myeloid Derived Suppressor Cells 
First gaining attention in the fields of tumors and cancer as a medical obstacle to 
overcome, Myeloid Derived Suppressor cells (MDSC) are now recognized as playing 
roles in other fields, such as transplant immunology (Highfill et al., 2010) and our 
current focus, autoimmunity (Yin et al., 2010).  MDSC, particularly noted for their 
potent suppressive activity, have been reported in some cases to even cause complete 
suppression of responding T cells at only comprising 3% of the cultured cells 
(Mazzoni et al., 2002).  MDSC are part of innate immunity.  They are comprised of a 
heterogenous population with the only determining characteristics being their 
suppressive function and phenotypic expression of CD11b and Gr-1  (mouse) (Bronte 
et al., 1998).  There are no clearly defined populations, although several general 
myeloid markers found in human MDSC.  In the mouse, the Gr-1-containing cells can 
be further differentiated by the expression of the glycoproteins lymphocyte antigens-6, 
Ly-6G and Ly-6C (Greifenberg et al., 2009; Ribechini et al., 2009).  The Ly-6 family 
has been described as phosphatidylinositol anchored cell surface glycoproteins.  The 
triggering of Ly-6 molecules results in various effects, including T cell activation 
(Ortega, 1986)(Malek, 1986) and migration (Hanninen et al., 2011).  Interestingly, the 
expression of Ly-6C and Ly-6G are not limited to just MDSC.  Ly-6C expression was 
observed upon others cell types including, but is not limited to, memory T cells, 
whereas Ly-6G is found, among others cell types, also on neutrophils.  CD11b+/Ly-
6ClowLy-6G+ subset represents the PMN-MDSC, whereas the CD11b+/Ly-6ChighLy-
6G- subset is the mono-MDSC (Movahedi et al., 2008).  These two subsets also can 
be differentiated by the nuclei.  PMN-MDSC exhibit a phenotypic ring nucleus while 
the monocytic fraction has a round nucleus consistant with cells of the monocytic 
lineage. MDSC residing in the spleen can be identified by their surface markers 
during steady-state (Ribechini et al., 2010), but only those isolated from mice 
containing tumors or inflammation are suppressive (Gabrilovich, 2012).  This lack of 
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suppression is thought to be caused by dilution of MDSC by other cells which are not 
suppressive, such as eosinophils, neutrophils, plasmacytoid DC and others, but 
expressing the same markers (Greifenberg et al., 2009).   Alternatively, it is 
hypothesized that steady-state MDSC lack stimulating signals required for their 
activation, therefore the diversion away from steady-state differentation into DC, 
macrophages, and granulocytes does not occur (Gabrilovich and Nagaraj, 2009).   
 
The generation of myeloid cells occurs in the BM.  Defined from hematopoetic stem 
cells, the myeloid cell lineage differentiates through a common myeloid precursor, 
where it then via appropriate signals can differentiate into common myeloid 
progenitor cells (Gabrilovich and Nagaraj, 2009).  These common myeloid progenitor 
cells differentiate into monocytes and/or IMC and can be further programmed into 
various cell types, such as DC, macrophages, and granulocytes, during steady-state, or 
under pathological conditions into MDSC (Gabrilovich and Nagaraj, 2009).  MDSC 
have reportedly require growth factors or cytokines i.e., GM-CSF (Dolcetti et al., 
2010), G-CSF, M-CSF, stem-cell factor (SCF), VEGF, IL-6, and IL-3, to regulate the 
differentiation of IMC and MDSC (Gabrilovich et al., 2012).  
2.2.1 Transcription factors relating to MDSC 
In tumors, various transcription factors are described to play roles in the generation or 
activation of MDSC (Gabrilovich, 2012).  Involved in general myeloid cell lineage 
development and therefore also involved in MDSC development and activation are 
several transcription factors, including CAAT/enhancer binding protein-beta (C/EBP-
b) (Auffray et al., 2009), PU.1 (Auffray et al., 2009), and signal transducer and 
activator of transcription (STAT) 1,3,6 (Greifenberg et al., 2009).  C/EBP-b has been 
reported to promote the generation of activated MDSC in vitro (Marigo et al., 2010) 
and mice deficient for C/EBP-b cells cannot differentiate into MDSC (Condamine and 
Gabrilovich, 2011; Hirai et al., 2006; Zhang et al., 2010).  It has not been clearly 
shown if C/EBP-b is required for differentiation or for activation.  
2.2.2 Myeloid derived suppressor cell activation 
IMC are known in different conditions to be activated by different factors 
(Gabrilovich, 2012).  Previously described factors which lead to the activation of 
MDSC are proinflammatory cytokines, IFN-g, and bacterial factors or inflammatory 
factors, such as the TLRs and IL-1b.  A combination of IFN-g and LPS leads to 
activation of MDSC.  This activation leads to nitric oxide production in supernatant 
and suppressive capacity when  tested in a MLR (Greifenberg et al., 2009).  
Pathogenic factors activate many different Jak-STAT pathways within the MDSC, 
which in turn activates nuclear factor kappa beta (NF-kB) leading to many effector 
functions, including NO (Gabrilovich, 2012).  Since the definition of this population 
is based on functionality, the specific factors can activate each subset differently, 
leading to different overall effector functions.  
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Figure I.4 Suppressive mechanisms of MDSC. A | induction of T regs, B | deprevation of amino 
acids, C | blocking T cell activation D | affecting migration through nitrosylation or cleavage of 
chemokines, direct “kill” signals, or release of anti-inflammatory cytokines. Figure from (Gabrilovich 
et al., 2012) 
2.2.3 Suppressive Capacity of MDSC 
The suppressive abilities of MDSC can be cell-cell contact based and/or soluble 
mediated.  The mechanisms employed by the MDSC can be the consumption of 
amino acids, the induction of T regulatory cells, or the release of short-lived soluble 
mediators, such as urea, NO, and other reactive oxygen species, which can denature 
the TCR (Gabrilovich and Nagaraj, 2009).  Mono-MDSC  primarily are the main 
producers of NO through inducible nitric oxide synthase (iNOS), whereas the PMN-
MDSC have been reported to use mostly arginase-1 (Arg-1) (Movahedi et al., 2008).  
MDSC subsets have been reported to produce the enzymes, Arg-1 and/or iNOS.  Both 
of which are mediators of L-arginine metabolism, therefore both can reduce the local 
quantity of L-arginine (Rodriguez et al., 2002).  In the case of Arg-1, its released from 
MDSC (Munder et al., 2006) suppresses is not only via decreasing the local L-
arginine, but also by increasing the concentrations of the metabolized L-arginine 
endproduct, urea.  Urea inhibits the re-expression of CD3-zeta chain in activated T 
cells after internalization, thus preventing activation signals (Rodriguez et al., 2002) 
(Figure I.4). iNOS expression in MDSC leads to the production of NO, a potent 
molecule controlling many functions.  In our in vitro based suppression assays, 
suppression by NO accounts for a considerable amount of the suppression.  In the 
case of T cells, NO nitrosylates tyrosine residues preventing activation signals into the 
T cell (Gabrilovich et al., 2012).  Molon et al. have also shown the ability of MDSC 
to nitrosylate chemokines (Molon et al., 2011). The combination of NO and Arg-1 
causes production of further modes of suppression, such as the creation of reactive 
oxygen species (ROS) (Gabrilovich et al., 2012).  Interestingly, Indoleamine 2,3-
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dioxygenase, an enzyme employed by T regs as a suppressive mechanism by 
depletion of the available tryptaphan, and NO inhibit each other (Hucke et al., 2004).   
 
MDSC suppress DC in many ways.  One mode of suppression occurs during the 
differentiation process by redirecting differentiation of DC-progenitors into MDSC, 
rather than the steady-state process, which normally would yield DC (Ribechini et al., 
2010).  Another way MDSC can suppress DC is through the release of NO, which 
inhibits MHC II expression on the DC, thereby removing their ability to present 
antigen (Harari and Liao, 2004).  NO from MDSC have been observed to inhibit T 
cell activation by preventing JAK-3 and STAT-5 activation, thereby inducing 
apoptosis in T cells (Gabrilovich and Nagaraj, 2009).  MDSC have other mechanisms 
by which it can suppress various cell types, but whether this suppression is antigen-
specific has remained controversial.  Reports have shown that MDSC require antigen-
specificity for their suppression (Solito et al., 2011).  Others state antigen specificity 
increases the suppressive capacity in a MHC II-dependent manner (Nagaraj et al., 
2012).  Contrary to these findings, others have described MDSC during hypoxic 
conditions can suppress non-specifically (Corzo et al., 2010). Other cell-cell contact 
mediated suppression has been observed. B7-H1 expression on MDSC can interact 
with PD-1 on Tregs to induce a Treg-mediated suppression during ovarian cancer (Liu 
et al., 2008).   
2.2.4 Migration of MDSC 
Auffray et al. have described two major monocyte populations differentiated by their 
expression of the cytokine receptor CCR2 and CXCR1 (Auffray et al., 2009).  CCR2 
expressing monocytes, namely classical monocytes, have been reported for their 
inflammatory migration, whereas CX3CR1hi monocytes, termed non-classical 
monocytes, have reported mostly as the precursor cells for resident myeloid cells 
(Auffray et al., 2009).  These two cell types have been observed to have differing 
expression of Ly-6C/Ly-6G (Gr-1) (Geissmann et al., 2003).  The CCR2 population 
has Gr-1 expression, whereas the CX3CR1 population does not.  Due to inflammatory 
signals during pathological times, monocytes are released from the BM using the 
CCR2 (Serbina and Pamer, 2006); these monocytes can also use this CCR2 to migrate 
into spleen and inflamed tissue (Geissmann et al., 2003).  
2.3 Autoimmunity  
Autoimmunity is the failure of self-tolerance, leading to reactivity against self 
antigens (Abbas AK, 2010).  Inflammation may be a prerequisite of consequence of 
autoimmunity.  The immune system has two ways to regulate itself: increasing pro-
inflammatory responses in the case of battling infection and increasing anti-
inflammatory responses, in the case of wound healing. These pro- and anti-
inflammatory responses are controlled by particular cytokines.  Central and peripheral 
tolerance evolved as a “checks and balances” way to keep the immune systems 
controlled (Abbas AK, 2010).  Cancer and autoimmunity are two ways in which the 
immune system can go awry.  Cancer usually results in immune suppression, whereas 
autoimmunity results in immune hyperreactivity.  Autoinflammation is driven by the 
innate immunity resulting in inflammation, whereas autoimmunity is caused by the 
adaptive immune system, primarily in auto-reactive T and B cells. Normally, the 
immune system can determine the difference between self and non-self antigens; 
therefore it only attacks those pathogen invaders, like bacteria and viruses, which find 
their way into the host.  During autoimmune diseases there is an attack of normal host 
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tissue causing massive inflammation.  This occurs primarily via adaptive immune 
responses such as auto-antibodies secreted from B cells or auto-reactive T cells 
(Abbas AK, 2010).    
 
Autoimmunity is usually accompanied by inflammation.  At the site of inflammation, 
the innate immune system releases reactive oxygen species, which may lead to the 
alteration of cell proteins.  Those altered glycoproteins and lipids on the cell surface 
then can be interpreted as foreign by the immune system (Moody and Besra, 2001). 
2.3.1 Multiple Sclerosis: The Disease 
Multiple sclerosis (MS) is a dehabilitating autoimmune disease characterized by the 
demyelination of nerves and axonal degradation caused by inflammatory conditions 
within the CNS (Glass et al., 2010).  This disease is devastating, largely because of 
the damage which occurs to the axons influencing motor function.  The cause of the 
disease is unknown, but studies have found that other diseases where viral lesions in 
the brain cause inflammation and infiltration of immune cells often result in a similar 
encephalopathy.  MS is a worldwide concern affecting at least 1 in 1000 people 
(Fugger et al., 2009).  There are four different classical MS types – relapsing 
remitting, primary progressive, secondary progressive, and progressive relapsing – but 
these are just broad categories as each person develops MS quite differently (Loma 
and Heyman, 2011).  The most common form is the relapsing remitting disease, 
characterized by its intermittent episodes (Loma and Heyman, 2011). Although 
women are more prone to develop MS (Fugger et al., 2009) due to its possible link 
with estrogen, both genetic and environmental factors have been suggested in 
initiating the disease (Ercolini and Miller, 2006).  Currently, MS is a tragic disease; 
while there are many therapies attempting to reduce the severity of the disease, there 
is no known cure to date.  
2.3.2 Animal model for MS: Experimental Autoimmune Encephalomyelitis  
Experimental Autoimmune Encephalomyelitis (EAE) is the commonly used mouse 
model for MS (Raine, 1984).  EAE most closely emulates the first episode of the 
relapsing-remitting model of MS.  EAE can be induced by a combination of an 
emulsion of myelin protein and oil-containing mycobacteria injected subcutaneously, 
providing a depot for slow release of self antigen, and i.p. injection of pertussis toxin, 
which among many functions opens the blood brain barrier (Hofstetter et al., 2002; 
Linthicum et al., 1982), induction of Th17 cytokines in the CNS (Zhao et al., 2008), 
and stops G-protein mediated migration, mimicks the first wave of the relapsing 
remitting disease in humans. Although the mechanisms which cause this immune 
attack on the myelin sheath have been studied in depth, there is still much left to be 
elucidated. All models of EAE are driven by auto-reactive CD4+ T cells against 
myelin proteins, most commonly used are myelin basic protein (MBP) and proteolipid 
(PLP), and myelin oligodendrocyte glycoprotein (MOG).  The importance of CD4 T 
cells within this model has been shown by the ability to induce EAE via the adoptive 
transfer of activated MOG-specific CD4 T cells, termed “passive” EAE (Stinissen et 
al., 1998).  Although EAE is considered to be a CD4 driven model, the effects of 
other cells playing a contributing role in EAE induction should not be discounted. 
Various reports have shown the role of CD8 T cells during EAE (Ford and Evavold, 
2005; Sun et al., 2001; Sun et al., 2003), whereas others have shown the importance 
of myeloid cells  and B cells.  The emulsion of peptide and complete Freund’s 
adjuvant (CFA) causes a relatively strong activation of cells in the local area, 
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activating the innate immune response.  CFA is the most commonly used way to 
induce EAE and other autoimmune diseases, as it serves as a depot, prolonging the 
lifetime of the injected antigen and the mtb component induces the expansion of 
Mac+ IMC (Billiau and Matthys, 2001).  Other adjuvants besides mtb, the major 
antigen component of CFA, have been shown to induce EAE; these include, CpG, 
LPS, Poly(I:C) and zymosan, which are TLR agonists (Mills, 2011). Interestingly, this 
TLR signalling is not required in the specific autoimmune-targeted organ for the 
induction of the disease (Hansen et al., 2006).  This local activation of DC, 
macrophages, and resident microglia activate the T cells, but to date, only a few 
reports of adoptive transfer of DC induced EAE (Weir et al., 2002).  One claim has 
shown the importance of the administration route, as only DC injected s.c., but not i.v. 
or i.p. could induce disease (Aghdami et al., 2008).  It is important to note that 
induction of other autoimmune disease models by DC has been shown.  DC are not 
only important for the activation of the autoreactive T cells, but help maintain local 
immune responses, perpetuating the disease (Ludewig et al., 1998) 
2.3.3 Multiple Sclerosis: Therapeutic FDA-Approved Drugs 
Currently offered for treatment of MS is the IFN-beta-1b therapy, with several drugs 
on the market including Avonex, Betaseron, Extavia, and Rebif (Loma and Heyman, 
2011).  IFN-beta, a type I interferon, is a cytokine normally released in response to 
viral infections to suppress the immune response.  IFN-beta has been shown to block 
IFN-g mediated disintegration of endothelial tight junctions (Minagar et al., 2003) and 
in vitro to enhance BBB integrity (Kraus et al., 2004).  When given IFN-b, patients 
with relapsing-remitting MS reduced severity and the duration of episodes by 
reducing the size, amount, and duration of lesions as observed by MRI (Gupta et al., 
2005).  Frequently, MS patients use combination therapy with the few other drugs on 
the market, with different active ingredients, such as glatiramer acetate (Copaxone), a 
fingolimod (Gilenya), and mitoxantrone (Novantrone) (Loma and Heyman, 2011).  
Natalizumab, a monoclonal antibody of vasculature cell adhesion molecule-1 
(VCAM-1), was another popular therapeutic drug until serious side effects limited it 
usage (Loma and Heyman, 2011).  This drug has been shown to block entry of cells 
into the CNS, but it also has been shown to have problematic side effects in patients 
that have a co-infection of JC virus (Loma and Heyman, 2011).  Currently, there are 
no cellular therapies in practice, although cellular therapy of Tregs has been shown 
promising for protection in EAE. 
2.3.4 Trafficking and Entry into CNS 
The blood-brain barrier (BBB) is a structure limiting entry from the blood into the 
brain, thereby regulating the movement of materials into and out of the neural organ.  
The BBB was discovered when trypan blue or evans blue dyes injected into the blood 
stream could not enter the CNS, and when injected into CNS did not exit to the 
periphery (de Vries et al., 1997).  This led to the belief that the CNS is an immune-
privileged organ.  Fairly recently, healthy individuals with an intact BBB showed, 
although limited in numbers, immune cells patrolling the CNS.  This changed our 
view of the CNS from an immune restricted organ to an immune-restricted organ 
(Romo-Gonzalez et al., 2012).  The difficult job of the immune cells is to protect the 
CNS from invading pathogens, while inducing the least possible bystander damage. 
The BBB normal restriction of entry into the CNS can be disrupted due to various 
causes.  Although unknown for MS, it has been suggested the leaky BBB may be 
induced by antibiotics, infection, or inflammation (de Vries et al., 1997).   Some 
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suggest BBB permeability is caused by co-infection of viruses, linking it to the release 
of IFN-g locally, as IFN-g, TNF-a, IL-1b, and IL-6 increase the permeability of tight 
junctions in vitro (de Vries et al., 1996; de Vries et al., 1997).  Interestingly, NO is 
indicated to decrease BBB permeablization (Wong et al., 2004).  Whatever the reason, 
the leaky BBB allows for the entry of re-activated T cells into the brain.  There are 
two cycles for entry of T cells in the brain; the first being the entry of Th1 cells into 
the spinal chord and subsequently release IFN-g inducing inflammation.  During the 
second round of entry, the Th17 cells enter through the choroid plexus via CCR6 - 
CCL20 dependent mechanism (Liston et al., 2009) and release IL-17 (Goverman, 
2009), inducing further chemokine recruitment of other cells to induce EAE 
pathology (O'Connor et al., 2008).  Rothhammer et al. has shown the entry 
requirements of Th1 cells are different than that of Th17 cells; Th1 cells require VLA-
4, whereas the Th17 require LFA-1 (Rothhammer et al., 2011).  Goverman showed 
the ratio of Th17 cells to Th1 cells is an important factor within the CNS in inducing 
inflammation (Goverman, 2009).  In the CNS, T cells interact with the activated 
microglia with high expression of MHCII and display myelin protein from 
surrounding damaged cells.  This interaction causes further activation of T cells by 
other myelin epitopes, in a process termed epitope spreading (Klehmet et al., 2004).  
This epitope spreading could be due to T cells containing dual TCR expression for 
both myelin proteins and possible viral proteins, as shown in EAE with CD8 cells (Ji 
et al., 2010).  Epitope spreading has been reportedly reduced by nitric oxide in EAE 
due to its regulation effect on autoreactive T cells (Fenyk-Melody et al., 1998; Shi et 
al., 2001).  Recognition of self can occur due to molecular mimicry of viruses with 
self (Stohlman and Hinton, 2001).  When confronting the challenges of a virus, the 
immune system can select T cells with certain epitopes to better adapt, but as the virus 
sequences are similar to self tissue molecules, host tissue may be attacked.  There is 
sequence homology between myelin basic protein, found in neurons, and human 
herpes virus 6 (Tejada-Simon et al., 2003) and Epstein Barr virus (Holmoy et al., 
2004; Lang et al., 2002; Wucherpfennig and Strominger, 1995).   
 
As microglia are the largest population of immune cells residing within the CNS 
(Gordon, 1986) and are innate immune cells, they act as first responders (Kreutzberg, 
1996) to any insult, such as pathogens, trauma, inflammation, with the brain.  In MS 
patients, the clustering of microglia, resident CNS cells similar to macrophages but 
normally lacking the expression of MHC II, are found before infiltrates and 
demyelination occur (Adams and Kubik, 1952; Seitelberger, 1973).  Upon activation, 
microglia upregulate MHC molecules, produce proinflammatory cytokines and NO, 
as well as can phagocytose pathogens, dead cells, and unfortunately in the case of 
multiple sclerosis, also myelin, the protective coating which ensheaths nerves 
(Nakajima and Kohsaka, 1993).  Roughly 30% of these CD11b+ cells within the brain 
are DC.    
 
It is known that during chronic inflammation the spleen is a site of systemic infection 
priming, whereas acute infections usually have the priming occur in the lymph nodes.  
EAE has been observed to have splenomegaly, an increased size of the spleen, due to 
increased influx of myeloid cells (Billiau and Matthys, 2001). Interestingly, GM-CSF, 
the growth factor we use to generate our BM-MDSC and also has been show to 
mobilize cells from the BM, is required for disease development of EAE as GM-CSF 
knockout mice are resistant to EAE, and neutralization of GM-CSF attenuates EAE 
(Roncarolo et al., 2006).  This role of GM-CSF in EAE pathogenesis may be due to 
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its ability to enhance TNF-a-induced IL-6 (Brissette et al., 1995) and the production 
of IL-23 (Sonderegger et al., 2008), both mediators of Th17 cells, by DC during the 
effector phase of EAE.  In addition, GM-CSF has been reportedly released from the 
Th17 subset (McGeachy, 2011).  Microglia have been reported to display a DC 
phenotype upon presence of high concentrations of GM-CSF in vitro (Esen and 
Kielian, 2007).  Interestingly, mice lacking GM-CSF are defective in myeloid cell 
recruitment to the brain (McQualter et al., 2001). Similar findings demonstrated 
administration of GM-CSF i.c. resulted in increased amount of cells phenotypically 
resembling DC with an activated phenotype (Mausberg et al., 2009).  Trafficking of 
monocytes which differentiate into antigen presenting dendritic cells and 
macrophages are important for the induction of disease, as these cells are required for 
the reactivation or priming of the T cells once they enter the CNS (Ifergan et al., 
2008).  Entry can also be caused by CCL2 upregulation within the CNS, which allows 
inflammatory cells to enter the perivascular cuffs, but does not necessarily cause any 
clinical signs of disease (Fuentes et al., 1995; Toft-Hansen et al., 2006). DC after 
migrating across the BBB and receiving GM-CSF and TGF-b signals have been 
shown to secrete Th1 and Th17 polarizing cytokines within the perivasculature cuffs 
(Ifergan et al., 2008). 
 
Although other cells contribute to the disease, it has been thought that MS is a T cell 
driven disease.  Flügel et al. have reported that MBP-specific T cells migrating to the 
spleen by day 3-4 after injection must be first primed in the spleen before heading to 
the brain (Flugel et al., 2001). Activated T cells and other inflammatory cells may 
enter the CNS via the interaction of very late antigen-4 (VLA-4) and vasculature cell 
adhesion molecule-1 (VCAM-1), which is upregulated in MS.  This interaction is 
specifically targeted in the case of the drug, Natizumab.   
 
 
Figure I.5  T cells priming and entry into CNS.  T cells get primed in the periphery and have two 
modes of entry into the CNS. Figure from (Goverman, 2009). 
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2.3.5 Suppressive Cellular therapies in EAE 
Cellular therapy, the application of supplementing an animal with cells to replenish 
the defective immunity, is not a new concept.  Cellular therapy has been studied 
extensively in mice, but now the application in humans is beginning to be accepted 
and even approved.  Interestingly, there are current trials using stem cell treatment to 
humans with MS, but as these trials are not finished, the results are unclear.  Previous 
studies have shown the adoptive transfer of Tregs in mice to be beneficial, i.e., 
dramatically reduced disease scores, when given as a treatment for EAE (Kohm et al., 
2002).  As discussed earlier, a mutation or lack in genes involving Foxp3 lead to very 
serious autoimmuity, i.e., IPEX mice.  Cellular therapies are not limited to T cells.  
Endogenous and adoptively transferred regulatory B (B10) cells have provided 
protection against EAE by a mechanism appearing to be independent of the those 
used by regulatory T cells (Matsushita et al., 2010).  Cellular therapies using the 
innate immunity have been employed.  Our lab has shown that BM-DC stimulated 
with TNF-a, which creates semi-mature DC, which can suppress EAE through 
immune deviation and activation of IL-10 producing Tr1 cells (Menges et al., 2002; 
Pletinckx et al., 2011). As these cellular therapies proved effective, we were interested 
in determining if MDSC can be applied in a similar manner. 
 
2.3.6 Myeloid Derived Suppressor Cells in Autoimmune Diseases/EAE 
When we began this project, there had not been much discussion about MDSC in 
autoimmune diseases.  Previous work was performed in analyzing the suppression of 
various adaptive immune cells, including CD8 and NKT, but most of this work was 
done in tumor and cancer settings (Ostrand-Rosenberg and Sinha, 2009).  Recently, 
there have been some reports on the ability of MDSC to suppress various disease 
models such as type I diabetes (Yin et al., 2010), GVHD (Highfill et al., 2010), and 
EAE (Zhu et al., 2007).  MDSC accumulation after CFA injection is described to be a 
reason why adjuvant therapy one cannot induce an immune response after boosting 
with CFA or live mycobacteria (O'Connor et al., 2012). 
 
MDSC were first described as a protective monocyte population observed during 
EAE (King et al., 2009).  During the peak of EAE, the CNS has shown 30% of 
infilitrates were immature monocytes, phenotypically with CD11b+Ly-6Chi F4/80 and 
CD93 (Zhu et al., 2007).  In this report, the authors analyzed the endogenous 
population kinetics, which increased during the disease to the peak in BM, blood, 
spleen and CNS (Zhu et al., 2007).  It has been shown using Gr-1 antibodies, which 
are known to bind the same epitopes as Ly-6C and Ly-6G cause the downregulation 
of the marker Ly-6C but not depletion (Ribechini et al., 2009) of myeloid cells, causes 
a delayed or completely protective effect (McColl et al., 1998).  As Ly-6C is a 
memory marker for T cells, the encephalitic T cells deletion could not be discounted 
from this study.  
 
It has been shown that GM-CSF release of Ly-6Chi precursors from the BM prevents 
exhaustion of the myeloid populations, possibly DC and macrophages, residing within 
the CNS, thus suggesting increased Ly-6Chi cells would be benefical to be applied to 
prevent demyelination (King et al., 2009).  Indications of suppressive cells within the 
lymph node have been reported as the transfer of lymph node cells, but not blood cells 
have been shown to prevent induced EAE (Englert and Hempel, 1981).  Another 
indication of the protective effect of IMC is a report discussing IMC in adjuvant 
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therapy, which protects from EAE, by the boost of CFA or live bacteria to the original 
CFA injection.  This action caused the expression of CXCR10 and CXCR16 attracted 
T cells to the draining LN rather than the CNS (O'Connor et al., 2012). 
 
During the course of our study, it was published that B7-H1 is required for the PMN-
MDSC fraction to be supressive late during EAE (Ioannou et al., 2012).  These 
researchers showed that the granulocytic subset given after EAE induction was the 
suppressive fraction. They also demonstrated that PMN-MDSC is no longer 
suppressive when it lacks the B7-H1 gene. 
2.4 Scope of Study 
One of the areas of focus of the Manfred B. Lutz laboratory at the University of 
Würzburg is to understand mechanisms of tolerance.  Our laboratory utilizes DC and 
MDSC to study different ways to manipulate the immune system to suppress 
unwanted responses in the cases of autoimmunity, transplant, and allergy, and to 
maintain tolerance during steady-state.  MDSC have been studied intensively in other 
fields, but little has been applied to autoimmunity.  As their negative effect of 
suppressing the immune system during times of tumors and cancer is an unwanted 
effect, we set out to see whether this effect, if manipulated, could be beneficial in 
overshooting responses, such as autoimmunity. Our ability to generate larger 
quantities of MDSC in vitro combined with the inducible EAE as a model allowed us 
the ability to assess these cells to suppress autoimmunity.   The aim of this project is 
broken up into three categories: 
 
 
1. The analysis of the factors leading to activation of MDSC. 
 
2. The identification of mechanisms MDSC utilizes to suppress T cell responses 
under both Th1 and Th17 conditions. 
 
3. The localization of IMC after i.v. injection. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Stimuli  
Stimulation with different compounds was used to analyze different factors activating 
BM-IMC into BM-MDSC. 
LPS 0.1 µg/ml (E.coli 0127:B8, Sigma-Aldrich), stored at -20°C. 
Curdlan 10 mg/mL in PBS (WAKO), particulate resuspension, stored at -20°C.  
Zymosan A 10 mg/mL stock in PBS (Sigma-Aldrich), particulate resuspension, use 
at 40 µg/mL, stored at -20°C. 
IFN-g 10 mg/mL in PBS (Peprotech), use at 1 µg/mL, stored at -20°C. 
IFN-b-1a 100 U/µL stock in dH20 (Peprotech), use at 500 U/mL, stored at -20°C. 
IFN-b-1b 100 U/µL stock in dH20 (Peprotech), use at 500 U/mL, stored at -20°C. 
IL-17 2 µg/mL stock in PBS (Peprotech), 10 ng/mL in PBS, stored at -20°C. 
Poly (I:C) 1 mg/mL stock in H2O (HMW, InvivoGen), 2 µg/mL in PBS, stored at 
-20°C. 
CpG 100 pMol/uL stock in PBS (Eurofins MWG/operon, sequence: 
TCCATGACTTCCTGATG), 600 pMol/mL in PBS, stored at -20°C. 
SEB 1 mg/mL stock (Sigma), use at 100 ng/mL or 10 ng/mL, stored at -
20°C. 
 
Stimulation with antibodies for proliferation of T cells: 
Anti-CD3 3.6 µg/mL, stock at 3.6 mg/mL (gift from Dr. Hünig, Würzburg), store 
at 4°C 
Anti-CD28 0.5 µg/mL, stock at 2.3 mg/mL (clone E18, gift from Dr. Hünig, 
Würzburg), store at 4°C 
3.1.2 Media, buffers, solutions 
Culture medias of cells: 
cRPMI:  
RPMI 1640 supplemented with 10 % of heat inactivated Fetal Calf Serum (Invitrogen, 
PAA gold), 2 mM L-Glutamine (PAA), 100 U/mL Penicillin and 100 µg/mL 
Streptomycin (PAA), 50 µM beta-mercaptoethanol (sigma). 
 
GM-CSF:  
Grown from hybridoma in cRPMI, yields roughly 400 ng/mL GM-CSF, use at 10% 
for culturing of BM-cells, supplemented every 3rd day. 
 
HL-1:  
HL-1 (Lonza) supplemented with 2 mM L-Glutamine (PAA), 100 U/mL Penicillin 
and 100 µg/mL Streptomycin (PAA), 50 µM beta-mercaptoethanol (Sigma-Aldrich). 
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Freezing Media:  
For cell (hybridomas) storage in liquid nitrogen. 10% DMSO (Sigma-Aldrich) and 
90% heat inactivated-Fetal Calf Serum (Invitrogen, PAA gold).  First freeze down in 
Mr. Frosty, containing iso-propanol at -80°C (for slow freezing process), once 
completely frozen for long term storage, place into liquid nitrogen. 
 
Buffers: 
4% Paraformaldehyde Solution:  
4 g Paraformaldehyde (Sigma-Aldrich) resuspended in PBS.  Sodium hydroxide was 
added to allow paraformaldehyde to dissolve.  Heated until 100oC for 1h (pH 7.4), 
stored for use at 4°C.  For fixation, use 10-30mins at 4oC. 
 
FACS Buffer (2.4G2 Supernatant):  
Hybridoma cell line grown in cRPMI producing an antibody specifically binding tp 
FcgRII/III, equivalent to Fc Block (CD16/32). 
 
Phosphate buffered saline (PBS) without Magnesium and Calcium:  
Calcium and Magnesium have been shown to activate DC, therefore we use the PBS 
without these components.  The solution consists of 4 mM KH2PO4, 16 mM Na2HPO4 
and 115 mM NaCl at pH 7.3. 
 
10X PCR Tissue Homogenization Buffer:  
A solution was made consisting of 500 mM KCl and 100 mM Tris in H2O, the pH 
was then adjusted to pH 8.  To this solution the following were added 0.1 mg/mL 
gelatine, 0.45 % Nonident P-40, 0.45 % Tween 20, 100 mL dH20.  The solution was 
then sterile filtered before use. 
 
RBC Lysis Buffer: 
Gey’s Solution: For removal of RBC. For 70 mL, 20 mL Stock A, 5 mL Stock B, 5 
mL Stock C and 40 mL sterile dH2O were combined.  The solution was filter through 
a sterile filter (without autoclaving) and stored at 4 °C or RT.  For lysis, 1 mL of 
Gey’s solution was added to splenocytes for 2 min.  The cells were washed 
thoroughly and spun down for use in different assays. 
 
Gey’s Stock Solution A  (1 L):  
NH4Cl (35 g), KCl (1.85 g), Na3PO4-12H2O (1.5 g), KH2PO4 (0.12 g), and glucose (5 
g) diluted in H2O. 
 
Gey’s Stock Solution B (0.1 L):  
MgCl2-6H2O (0.42 g), MgSO4-7H2O (0.14 g) and CaCl2 (0.34 g) diluted in dH2O. 
 
Gey’s Stock Solution C (0.1L):  
NaHCO3 (2.25 g) diluted in dH2O. 
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3.1.3 Griess Reagent: 
For analysis of NO production through nitrite detection.  For working reagent, Griess 
Reagent A was mixed in equal volumes of Griess Reagent B fresh for every usage.  
Then Griess Reagent A/B was mixed with equal amounts of supernatant.  Reaction 
was allowed for 10 minutes.  Colormetric assay was run on the Spectramax at 492 nm. 
 
Griess Reagent A:  
0.1 % Naphthylethylenediamine dihydrochloride (Sigma) in dH2O. Stored at 4oC; 
away from light. 
 
Griess Reagent B:  
1 % Sulfanilamide (Sigma) in 5 % H3PO4/dH2O. Stored at 4 °C. 
 
Standard:  
NaNO2  
 
3.1.4 Anaesthesia: 
Sleeping Mouse Kax:   
For roughly 10 mice.  Injections administered i.p. at 100 µL/mouse, solution of 144 
µL Ketavet (Ketamin at 100 mg/mL), 90 µL Rompun (Xylazin 2%; 10 mg/mL), and 
760 µL PBS was prepared. 
 
Lethal Anesthesia:  
For roughly 30 mice injections ip at 70 µL/mouse a solution of  1440 µL Ketavet 
(Ketamin at 100 mg/mL), 900 µL Rompun (Xylazin 2%; 10 mg/mL), and 760uL PBS 
was prepared. 
 
Isofluran:  
Isofuran inhalation was given to anesthesize mice during EAE induction.  Sleeping is 
induced through inhalation.  The oxygen was controlled, level 2 mixing with water 
and Level 3 isofluran to anesthesize mice.  Mice were then placed into a chamber for 
the initial anesthesia, followed by placement of only the head into a nozzle during 
injections. 
 
CO2 afixiation:   
CO2 was given to until mice were completely afixiated, followed by cervical 
dislocation to assure mice were sacrificed. 
 
SANDWICK DOCTORAL THESIS, JUNE 2012! MATERIALS AND METHODS 
 
P a g e | 35  
 
3.1.5 In vivo tracking 
D-Luciferin firefly:   
4 g of D-luciferin (Biosynth) was reconstituted in 165 ml aqua-dest H2O.  Aliquots 
were stored at -20 °C.  Mice were injected with 200 µL i.p. with 200 µL of mouse kax 
(sleeping) i.p. and 10 minutes were allowed for complete circulation and for best 
signal for imaging. 
 
CFSE:   
CFSE labels intracellular proteins within the cell.  The cells then are visable in the 
FITC channel.  Stock concentration is 5.6 mM.  Aliquots are stored at -20°C.  Cells 
were labeled for in vitro proliferation assays at 0.93 µM, whereas cells injected in vivo 
were labeled with 1.87 µM in PBS. 
 
eFluor 670:   
eFluor670 (eBioscience) labels cells in a similar way to that of CFSE, with the 
exception that it labels the cells so they are visable in the APC channel. Stock 
concentration is 5 mM.  Aliquots are stored at -20 °C.   
 
CM-DiI:   
CM-DiI (Molecular Probes, Invitrogen) is a membrane labeling lipophilic dye.  Stock 
is stored frozen at -20 °C, freshly diluted with DMSO for the concentration of 2 
mg/mL.  The dye is used by incubating 107 cells in PBS with 10 µM (1 / 200 dilution) 
of the stock dye for 5 mins at 37 °C followed by a 15 min incubation at 4 °C. Cells are 
visable in the PE channel.  
 
3.1.6 Radioactive [3H] Thymidine  
Radioactive [3H] thymidine: To assess proliferation, a radioactively labeled isotope 
of thymidine was added to cells.  This intercalates into the DNA, as the cells divide 
there will be a brighter signal.  A 50 µCi/mL solution was prepared by dilution of [3H] 
thymidine (Hartmann Analytic) in serum free media.  The concentration used in the 
assay was 1 µCi/well in a 96 well plate.  
 
3.1.7 Experimental Autoimmune Encephalomyelitis 
Oil-water emulsion was created using 1:1 ratio of CFA containing extra heat-killed 
Mtb to MOG peptide.  Emulsion was performed using a three-way stop cock. 
 
MOG35––55 Peptide (EVGWYRSPFSRVVHLYRNGK):  
A solution was prepared at 2mg/mL in ddH2O by dilution. (Synthesized by HPLC, 
Charite, Berlin) 
 
Pertussis toxin:  
A solution was prepared by dilution at 0.1 µg/uL in PBS. (List Biological 
Laboratories)  
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Complete Freund’s Adjuvant (CFA):  
10 mL vial (Sigma-Aldrich) containinig 1 mg of Mtb and 10 mL oil. 
 
Heat killed Mycobacteria (strain H37RA):  
10 mg vial (DIFCO Laboratories) 
 
3.1.8 Enzymes and inhibitors   
L-NMMA:  
An inhibitor of iNOS.  Stock solution diluted first in DMSO, then in RPMI at 50 mM.  
This solution was then diluted into cell culture at 500 ug/mL. 
 
3.1.9 GM-CSF Supernatant 
Supernatant was obtained as previously published by Stockinger et al (Zal et al., 
1994).  In brief, GM-CSF gene transfected plasmacytoma X63-Ag8 cell line was 
cultured in cRPMI medium until medium was orange-yellow.  The cells were then 
pelleted, supernatant was taken, and filtered through a 0.2 µm filter.  The supernatant 
was then tested via ELISA to assure the concentration was above 400 ng/mL.  
Supernatant was frozen at -20 °C until use.  Supernatant was used at 10 % in growth 
of BM-DC and BM-IMC cultures. 
 
3.1.10 Mice 
Mice were used at 6 – 16 weeks of age.  Mice were bred in the animal facilities of the 
center for molecular medicine (ZEMM) and of the Institute for Virology and 
Immunbiology, University of Würzburg, Würzburg, Germany, or at Charles River.  
Breeding pairs for C57Bl/6 PD-1-/- and C57Bl/6 B7-H1-/- mice were a kind gift of 
Heinz Wiendl, Neurology Clinic, Würzburg University. Albino.C57Bl/6J and 
Luciferase+ CD45.1+ C57Bl/6J mice were kindly provided by Andreas Beilhack, 
ZEMM, Würzburg University. 
 
BALB/c 
A mouse used for allo-MLR because of its different MHC genes I-Ab) 
 
C3H.TLR4-/-/MyD88-/- (control C3H.TLR4-/-) mice 
A transgenic mouse which lacks MyD88 adaptor protein and the TLR4 gene. The 
control mice lack only the TLR4 gene.  (Provided as a gift by Andre Gessner, 
formerly of Uni-Erlangen) 
 
C57BL/6J 
Our control mouse.  MHCII molecules are all I-Ad 
 
C57Bl/6J.albino mice 
A transgenic mouse containing a changed for the hair color allele. This mouse 
provides less interference of the luciferase bioluminescence compared to black hair 
counterparts. (Provided as a gift by Andreas Beilhack, ZEMM, Würzburg). 
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C57Bl/6J.B7-H1-/- mice 
A transgenic mouse which lacks the gene B7 homologue 1 (B7-H1).  This is one of 
the ligands which interacts with PD-1, therefore it was used for analysis of the PD-1 : 
B7-H1 interaction. Confirmation was performed via PCR for the neocassette. 
(Provided as a gift by Heinz Wiendl, Neurology Clinic, Würzburg).  Mouse line made 
by Lieping Chen. 
 
C57Bl/6.IFN-gR1-/- mice 
These mice lack the interferon gamma receptor. (Provided as a gift from Dr. Ulricke 
Schieber/Dr. Christian Bogden) 
 
C57Bl/6.iNOS-/- mice 
These mice lack inducable nitric oxide synthase. (Provided as a gift from Dr. Ulricke 
Schiecher/Dr. Christian Bogden) 
 
C57Bl/6.IRF-1+/- and C57Bl/6.IRF-1-/- mice 
These mice lack the signalling gene for Interferon regulatory factor-1 either in one 
allele (IRF+/-) or both allels (IRF-/-). (Provided as a gift from Dr. Micheal Lohoff, 
Marburg) 
 
C57Bl/6J.Luc+CD45.1 mice 
A transgenic mouse contain a luciferase-expressing L2G85 reporter gene construct, 
which had been inserted through a pronuclear injection into FVB/N mice (Cao et al., 
2004) and subsequently backcrossed over 14 generations on to C57BL/6 mice.  
Luciferase cleaves a substrate called luciferin which allows for in vivo analysis. These 
mice also have the allele for CD45.1 that allows differentiation from C57Bl/6 mice 
which express the CD45.2 allele.  (Provided as a gift by Andreas Beilhack, ZEMM, 
Würzburg)  Confirmation was performed via PCR in the Beilhack lab. 
 
C57Bl/6J.Luc+IFN-aR-/- mice 
These mice lack IFN-I receptor genes.  A transgenic mouse which produces luciferase. 
(Provided as a gift by Christine Krempl, Virology, Würzburg)  
 
C57Bl/6J.OTII mice 
These mice are transgenicly altered so that the TCR of CD4 T Cells is specific for the 
recognition of OVA.  
 
 C57Bl/6J.PD-1-/-   
A transgenic mouse which lacks the gene for programmed death receptor-1 (PD-1).  
Used for analysis of the PD-1-B7-H1 interaction.  Confirmation for the loss of PD-1 
is performed via PCR for the neo-cassette.  (Provided as a gift by Heinz Wiendl, 
Neurology Clinic, Würzburg).  Line made by Honjo. 
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C57Bl/6J.VAV-CRE mice 
These mice have the expression of the CRE-recombinase under the VAV promoter.  
This promoter is expressed in all cells, therefore all cells within this mouse have the 
expression of CRE.  This mouse is generally used for breeding with mice that have 
lox-p sites, which allows for the mouse to lack a particular gene as the CRE 
recombinase can cleaves these sites.  These mice were used as control mice for these 
mice which lack the gene.  (Provided as a gift from Dr. Friederike Bereberich-Siebelt, 
Pathology, Würzburg.) 
 
C57Bl/6J.VAV-CRE X CAAT/enhancer binding protein-beta fl/fl mice 
These mice lack the expression of C/EBP-b.  When activated VAV-CRE promoter, in 
all cells, when activated then can cleave the flox sites around the C/EBP-b, which 
excizes the gene.  (Provided as a gift from Dr. Friederike Bereberich-Siebelt, 
Pathology, Würzburg.) 
3.1.10.1 Antibodies  
Primary Antibodies: 
Antibody Company Staining 
CD11b Biolegend Surface 
Ly-6C  BD Surface 
Ly-6G Biolegend Surface 
CD80 BD Surface 
CD86 BD Surface 
CD40 Miltenyi Surface 
PD-1 eBioscience Surface 
B7-H1 BD Surface 
CD4 Biolegend Surface 
CD8 Biolegend Surface 
IL-17 eBioscience ICC 
IFN-g BD ICC 
Foxp3  eBioscience Intranuclear 
Ki67 BD Intranuclear 
 
Secondary antibodies: 
Anti-Rat Alexa 647 (Jackson Labs) 
3.2 Methods  
3.2.1 Harvesting, and culturing Primary murine cells  
Bone Marrow Immature Myeloid Cells and Immature Dendritic Cells 
Mice were sacrificed for their BM.  The skin around the hind legs was trimmed off 
and the feet were cut at the ankle joint.  The leg bones were separated from the 
pelvic/hip bone.  The muscle/tendons were cleaned off via rubbing a paper towel over 
the bones.  Bones were then placed in ethanol for one minute.  The ends were then 
clipped off with scissors.  The BM was then flushed out using a 10 mL syringe with a 
27 gauge needle (grey) containing PBS.  The BM was collected in a 15 mL conical 
tube, spun down to a pellet, and resuspended in cRPMI.  Cells were counted and 
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plated at 3X106 cells/10 cm sterile petri dish in a total of 10 mL cRPMI supplemented 
with GM-CSF.  Cells were incubated in a 7% CO2 incubator.  BM-IMC can be 
harvested at day 3.  Immature DC need to be fed with 10 mL cRPMI supplemented 
with GM-CSF on day 3 and day 6 for use on day 8.  
Splenocytes 
Mice were sacrificed and spleens were collected.  A single cell suspension was 
created by mushing the whole spleen through a plastic cell strainer (0.2 µm) to create 
a single cell suspension.  Cells were then spun down, resuspended in Geys solution 
for 1-3 min, washed and spun down in PBS.  The cells were then resuspended in 
cRPMI.  For samples with injected BM-IMC, the collagenous bundle found in spleen 
would then be separated.  To make a single cell solution, DNAse I (1mg/mL, Roche) 
and Collagenase III (1mg/mL, Wothington, CA) were added for 20 min at RT.   
Lymph nodes 
Mice were sacrificed and inguinal lymph nodes are collected. A single cell suspension 
is created by mushing whole lymph nodes through a plastic cell strainer (0.2 µm) to 
create a single cell suspension.  Cells were then spun down and resuspended in 
cRPMI for tissue culture or for FACS analysis. 
Central Nervous System: Isolation of Lymphocytes 
Mice were sacrificed and brain and spinal chord were removed.  The organs were then 
cut into small pieces, incubated with DNase I (1mg/mL, Roche) and Collagenase NB4 
(1 mg/mL, Serva) for 45 mins.  The cells were then lysed through a needle 
resuspended in 30 % Percoll and placed over a 70 % Percoll gradient.  The cells were 
then spun down without a break for 30 mins.  The lymphocyte fraction of cells, found 
within the buffy layer, were then washed and spun down.  Cells were then 
resuspended in cRPMI and used for further analysis. 
3.2.2 Stimulation   
Stimulation of Bone marrow generated immature myeloid cells 
BM-IMC were stimulated using concentrations listed in the materials section.  
Stimulation was performed in particular ways for each assay.  BM-IMC were 
stimulated overnight for analysis of surface markers and intracellular cytokines.   BM-
IMC were placed into MLRs for three days. 
T cells Restimulation 
Splenocytes were harvested (see above) and cells were seeded at 4X105 cells/well in a 
96 round bottom plate in a total of 200 µL/well.  Specific memory responses were 
analyzed via addition of different concentrations of MOG peptide, or aspecific 
stimulation could be analyzed by addition of anti-CD3/anti-CD28 antibodies. 
3.2.3 Sorting Immature Myeloid cell subsets via MACS 
BM-IMC were generated as normal.  D3 bulk cultures were then sorted using Ly-6G-
Biotin antibody, incubating in 2.4G2 supernatant for 30mins at 1:100 µL, Samples 
were washed.  Resuspended in PBS and incubated with anti-biotin MACS-microbeads 
(Miltenyi Biotec) for 30 minutes.  Washed with PBS.  Cells were placed over a MS 
column for positive selection of Ly-6G.  Cells which flowed through were the Ly-6G 
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negative fraction.  Columns were washed and plunged to receive the Ly-6G positive 
fraction.  
 
3.2.4 Fixation of subsets for MLR 
Cells were sorted using MACS the incubated overnight in cRPMI supplemented with 
GM-CSF.  The previously described protocol for fixation and washing by Munster et 
al was slightly modified.   Briefly, cells were harvested and fixed with 4% PFA for 30 
mins, then washed with PBS and then placed in cRPMI overnight to wash out any 
residual PFA which might affect the interaction with the T cells.  Cells were then 
added to EAE splenocytes restimulated with either anti-CD3/anti-CD28 or with MOG 
peptide at 10 µg/mL. 
3.2.5 Proliferation 
CFSE 
Cells (bulk splenocytes) were stained in 10.5 mL of PBS for 15 mins at RT.  The 
CFSE is neutralized by FCS and then washed.  T cells were then incubated for 6 days 
in a CO2 incubator. 
[3H] Thymidine Incorporation 
Culturing: 
Cells were cultured in a 96 well plate containing 200 µL/well for 2 days at 7% CO2. 
Pulse: 
Radioactive [3H] -methyl-thymidine is reconsitituted in serum free media at the 
concentration of 50 µCi/mL.  For proliferation assessment, 20 µL/well was added 
providing each well 1 µCi per a total of 200 µL cell solution. 
Harvest: 
Harvest was performed using a Tomtec 96-well harvester (PerkinElmer).  The 96 well 
plates were first harvested onto glass-fiber filters (PerkinElmer).  The filter was then 
dried in an incubator for over an hour.  Followed by the addition of Scintallation 
buffer.  Each filter was then heat sealed in an individual plastic sample bag 
(PerkinElmer) and counting, as performed by the 1450 Microbeta counter.  Readouts 
were given in Microsoft Excel format. 
 
3.2.6 Flow cytometry 
Flow cytometry: Surface Marker Staining 
Staining is performed in 100 µL of 2.4G2 supernatant at 1:100 dilution of antibody.  
Cells were then incubated at 4°C for 30 mins.  Cells were then washed and either 
aquired by FACS LSRII using FACS-Diva software.or continued using intracellular 
or intranuclear staining.   
 
Flow cytometry: Intracellular Staining  
Staining was performed as normal using cell surface staining protocol (see above).  
Cells were then fixed with 4 % PFA for 30mins.  Cells were then washed with PBS, 
spun down, and resuspended in permeabilization solution (0.5 % Saponin) for 30 
SANDWICK DOCTORAL THESIS, JUNE 2012! MATERIALS AND METHODS 
 
P a g e | 41  
 
mins.  Cells were then spun down and resuspended in 100 µL Perm Buffer containing 
1:100 dilution of antibody.  Cells were then incubated for 1 h at 4°C.  Cells were 
washed with PBS to remove the Saponin and aquired by FACS LSRII using FACS-
Diva software. 
 
Flow cytometry: Intranuclear Staining (Foxp3, eBioscience kit) 
Staining was performed as normal using cell surface staining protocol (see above).  
Cells were then fixed with 100 µL Fix/Perm buffer (eBioscience, freshly diluted 1 
part fixation/permeabilization concentrate with 3 parts Fix/Perm buffer) for 30 mins.  
Cells were then spun down, resuspended in 100 µL Perm solution (eBioscience, 
freshly diluted 1 part permeabilization buffer diluted in 9 parts dH2O) for 30mins. 
Cells were then spun down and resuspended in 100 µL Perm Buffer containing 1:100 
µL dilution of antibody.  Cells were then incubated for 1 h at 4°C.  Cells were washed 
with PBS to remove the perm buffer and aquired by FACS LSRII using FACS-Diva 
software. 
 
Flow Cytometry: Flow Jo Analysis  
Events aquired on FACS-Diva software was then analyzed using Flow jo software 
(Treestar).  Statistics of percentages were calculated using Microsoft Excel. 
 
3.2.7 Histology by Immunofluorescence staining  
Staining for surface antigens (CD169 ) 
Fresh frozen tissue was fixed for 30 min with 4% PFA.  Tissue was then blocked 
using Blocking buffer (5% BSA in PBS with 0.3% TritonX) for 30 min.  Tissue was 
then stained overnight with antibodies (1:100) in staining buffer (1% BSA in PBS 
with 0.3% TritonX).  Tissue was washed three times for 5 min.  Tissue was then 
incubated for 1 h with secondary antibody (1:300) in staining buffer (1% BSA in PBS 
with 0.3% TritonX).  Tissue was washed three times for 5 min.  Tissue was 
coversliped with Fluoromount G and analyzed via Fluorescent microscopy. 
 
3.2.8 Cell tracking 
Biolumenescence in vivo Imaging 
Mice were injected with 200 µL anaesthesia and 200 µL luciferin. Ten minutes were 
given to allow to luciferin to circulate the entire mouse.  The mouse was then placed 
under a camera.  The same settings were used every time with 5 min exposure.  The 
photons emitted from the cleavage of the luciferin by the cells are captured into 
pictures.  These pictures were then overlayed onto a normal photograph of the 
mouse/organ to display where the emission was located.  Analysis was performed by 
gating with ROI generates the Photons/second within the area of interest.  These 
values can be graphed with Microsoft Excel. 
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3.2.9 Soluble factors 
Nitric Oxide  
Released NO is measured via a colormetric assay.  To 50 µL supernatant, 50 µL of 
freshly mixed Griess Reagent (see above) was added and incubated for 10 min. The 
NaNO2 concentration of samples and standards was measured at 492 nm.  Standard 
curves were created based on the NaNO2 optical density (OD) readings.  From this 
standard curve, samples concentrations were calculated. 
 
Enzyme linked immunoabsorbant Assay  
Enzyme linked immunoabsorbant Assay (ELISA) is a very common technique 
involving antibodies followed by an enzyme-substrate color forming reaction to 
quantify how much of an antigen is in sera or supernatant.  In this case, GM-CSF 
ELISA were performed using the instructions suggested by the manufacturer (BD 
Optia kits). 
 
3.2.10 PCR 
PCR for B7-H1-/- mice 
Ear notches were taken from mice and diluted in a 1x Tissue homogenization buffer 
containing a 200 µL of buffer and 5 µL of proteinase K/ sample.  Samples were then 
digested overnight at 56 °C.  Inactivation of proteinase K was performed at 96 °C for 
10 mins.  PCR was performed useing reagents from Fermentas.  The master mix 
included 10x ammonium sulfate buffer, 25 mM MgCl2, 10 mM dNTP, 10 µM 
primers, 5 U/µL Taq polymerase, water and 1 µL digested tissue DNA for a total of 
25 µL.  
Primer sequences: 
Primer sequences were synthesized by Sigma-Aldrich. 
 
B7-H1 FOR:  5‘AGAACGGGAGCTGGACCTGCTT~GTTAG3‘ 
 REV: 5 ‘ATTGACTTTCAGCGTGATTCGCTTGTAG 3‘ 
 NEO: 5 ‘TTCTATCGCCTTCTTGACGAGTTCTTCTG 3‘ 
PCR Program: 
Thermocycling was performed using an initial 2 min hot start at 94 °C, followed by 
40 cycles of 30 s at 94 °C (Denaturing), 30 s at 60 °C (Annealing), 8 s at 72 °C 
(Elongation), and completed with another 30 s at 72 °C (final Elongation) before 
holding at 4 °C.  
PCR Product lengths: 
PCR products were run on a 2 % agarose gel (0.5% TBE buffer and corresponding 
amount of agarose, boiled, followed by addition of ethidium bromide) at 100V.  The 
WT PCR product is 250 bp in length while the B7-H1-/- band detected by the neo 
cassette is 450 bp in length. 
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PCR for PD-1-/- mice 
Ear notches were taken from mice and diluted in a 1x Tissue homogenization buffer 
containing a 200 µL of buffer and 5 µL of proteinase K/ sample.  Samples were then 
digested overnight at 56 °C.  Inactivation of proteinase K was performed at 96 °C for 
10 mins.  PCR was performed useing reagents from Fermentas.  The master mix 
included 10x ammonium sulfate buffer, 25 mM MgCl2, 10 mM dNTP, 10 µM 
primers, 5 U/µL water and 1 µL digested tissue DNA for a total of 25 µL.  
Primers sequence: 
Primer sequences were synthesized by Sigma-Aldrich. 
PD-1 FOR:   5’ CCG CCT TCT GTA ATG GTT TG 3’ 
 REV:  5’ TGT TGA GCA GAA GAC AGC TAG 3’ 
 
NEO FOR:   5’ GCC CGG TTC TTT TTG TCA AGA CCG A 3’ 
 REV: 5’ ATC CTC GCC GTC GGG CAT GCG CGC C 3’ 
PCR Program: 
Thermocycling was performed using an initial 2 min hot start at 94 °C, followed by 
35 cycles of 30 s at 94 °C (Denaturing), 30 s at 54 °C (Annealing), 45 s at 72 °C 
(Elongation), and completed with another 30 s at 72 °C (final Elongation) before 
holding at 4 °C.  
 
PCR Product lengths: 
PCR products were run on a 2 % agarose gel (0.5% TBE buffer and corresponding 
amount of agarose, boiled, followed by addition of ethidium bromide) at 100V.  The 
WT PCR product is 690 bp in length while the PD-1-/- band detected by the neo 
cassette is 400 bp in length. 
 
qRT-PCR for Arginase-1 mice 
Splenocytes we placed into 1mL of Trizol (Ambion) at 2X106/mL. 
RNA Isolation: 
To thawed trizol samples, 200 uL of Chlorophorm was added.  Samples were shaken 
hard by hand for roughly 20 s.  Samples were then incubated on ice for 5mins.  Before 
spinning down, samples were then shaken hard by hand for another roughly 20 s.  The 
aqueous phase (clear portion) was removed and placed into new eppendorf tube.  
Isopropanol was added in equal volumes.  Samples were shaken hard by hand for 
roughly 20 s, followed by an incubation on ice for another 5 mins.  Samples were 
spun down and supernatant was removed, recovering only the pellet.  The pellet was 
washed 2 times with 70 % Ethanol.  Samples were allowed to air-dry.  Concentration 
of the isolated RNA was observed using the Nano-drop technology. 
DNAse Reaction: 
DNA was removed from the samples using DNase I (Roche).  Extracted RNA was 
incubated in a solution containing 10x reaction buffer, DNase I (1U/µL) and H2O at 
37°C for 15 mins, 50 mM EDTA was added followed by another incubation at 65°C  
for 10 mins.  Samples were then read for reverse transcription into cDNA. 
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cDNA: 
Reverse transcription was performed to obtain cDNA.  To do so, RNA was added into 
a master mix containing Oligo(dt)18 primer with DEPC H2O.  This solution was then 
mixed and incubated at 70 °C for 5 mins.  The mix was then added to a secondary 
master mix containing 10 mM dNTP, 5X reaction buffer, BioScript Reverse 
Transcriptase enzyme (Bioline), and DEPC H2O.  This solution was then incubated at 
45 °C for 1 h, followed by subsequent incubation of the samples at 70 °C for 10 mins.  
Samples were then stored at 4 °C 
qRT-PCR: 
Samples were prepared for analysis by qRT-PCR.  2 µL of cDNA was added to SyBr 
green master mix containing 2x SYBR green and light cycler H2O and forward and 
reverse primers (5 µM, Sigma-Aldrich.).  Arg-1 primer sequences were selected from 
a paper discussing Arg-1 in murine macrophages (Pourcet et al., 2011).  18S, due to 
its stability, and that myeloid cells upon activation increase beta-actin, was selected as 
the control (Bas et al., 2004; Schmittgen and Zakrajsek, 2000). Sequence for the 18S 
primers was selected from (Schmittgen and Zakrajsek, 2000).  
 
Arg-1 FOR: 5’   GGAATCTGCATGGGCAACCTGTGT   3’ 
REV: 5’   AGGGTCTACGTCTCGCAAGCCA   3’ 
 
18S  FOR: 5’   GTAACCCGTTGAACCCCATT    3’ 
REV: 5’   CCAT CCAATCGGTAG TAGCG   3’ 
Program: 
Thermocycling was performed using the iCycler (BioRad) an initial 15 min hot start 
at 94 °C, followed by 40 cycles of 30 s at 94 °C (Denaturing), 30 s at 60 °C 
(Annealing), 30 s at 72 °C (Elongation), and completed with another 1 min at 95 °C 
and 1 min at 60°C (final Elongation).  Temperature was then placed at 55 °C and 
incrementally increased every 15 s after the initial 30 s.  
Analysis: 
Values obtained qRT-PCR were further analyzed using Microsoft Excel.  Arg-1 
values were subtracted from the control (18S) values obtaining a value considered 
delta CT.  The delta CT values of the experimental group (EAE + BM-IMC) were 
subtracted from the average delta CT values of the control group (EAE), this value is 
considered deltadelta CT.  To assess the logarithmic phase of the PCR values were 
analyzed using the formula [2 (-deltadeltaCT)]. 
 
3.2.11 Induction of Experimental Autoimmune Encephalomyelitis  
BM-IMC were injected i.v. 3 to 4 days before induction. BM-IMC injected mice were 
immunized with 150 µg of the myelin oligodendrocyte glycoprotein (MOG35-55) 
peptide emulsified in complete Freund's adjuvant followed by administration of 
pertussis toxin on day 0 and day 2. 
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4 RESULTS 
4.1 Confirming bone marrow generation of myeloid derived suppressor cells 
and their corresponding splenic myeloid derived suppressor cell subsets in 
untreated wildtype C57Bl/6 mice  
MDSC, described by their CD11b, Gr-1 expression and suppressive function, are 
normally found in low quantities within the normal untreated WT mouse (2-4%) 
(Gabrilovich and Nagaraj, 2009; Kusmartsev and Gabrilovich, 2006). As Gr-1 can be 
broken down into two further markers, utilizing these surface markers identifies two 
subsets, PMN-MDSC (Ly-6Clow, Ly-6G+) and Mono-MDSC (Ly-6Chigh, Ly-6G-) 
(Bunt et al., 2006).  To confirm our ability to phenotype MDSC ex vivo, we 
performed surface stainings of spleens and could confirm this population makes up 
roughly 2% of our steady-state spleens (Figure R1). Unfortunately, with the yield 
being only 2% of the spleen and the fact that these populations are not suppressive 
during steady-state conditions (Ribechini et al., 2010), made it hard to utilize it as a 
cellular therapy.  Therefore, we switched to BM-MDSC generation by culturing BM 
in the presence of GM-CSF for 3 days as previous established by Roßner et al. This 
BM-MDSC protocol allows the generation of a considerable amount of cells, of 
which can suppress proliferating T cells (Rossner et al., 2005).  To confirm that we 
could generate the same cells, we flushed BM from WT C57Bl/6 mice and cultured 
them in the presence of GM-CSF for 3 days creating BM-IMC. The cells expressed 
CD11b, Ly-6C, and Ly-6G, consistant with previous findings in the lab (Figure R2).  
To assess functionality, cells were stimulated overnight with LPS and IFN-g to push 
the cells into BM-MDSC, which have been described to produce NO and suppress T 
cells.  We could confirm BM-MDSC can produce NO compared to the untreated BM-
IMC and they can supress when added to stimulated splenocytes (Figure R2).  
 
Figure R1.  Phenotype of splenic cells from C57Bl/6 mouse.  
A single cell solution was made from spleens from untreated WT C57Bl/6 mice.  Briefly, spleen cells 
were filtered through a T-cup strainer, and RBC lysed for flow cytometric analysis.  Flow cytometry 
staining for MDSC markers CD11b, Ly-6C, Ly-6G markers. Plot show is representative of many 
experiments. 
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Figure R2.  Phenotype and functionality of BM-MDSC from C57Bl/6 mouse.  A | BM-BM-IMC 
Phenotype. D3 BM-IMC grown in the presence of GM-CSF from a WT C57Bl/6 mouse.  Flow 
cytometry staining for MDSC markers CD11b, Ly-6C, Ly-6G.  Plots shown are representative of many 
experiments. B | D3 BM-IMC were stimulated with LPS/IFN-g overnight or left unstimulated.  
Supernatants were analyzed for NO production using the Griess Reagent. Plot show is representative of 
many experiments. C | D3 BM-IMC were added to anti-CD3/anti-CD28 stimulated C57Bl/6 
splenocytes.  Cells were incubated for 2 days then pulsed with radioactively labeled [3H] thymidine to 
assess proliferation. Plot show is representative of many experiments.  
 
4.2 CAAT/enhancer binding protein-beta may influence development and 
activation of mono-BM-MDSC. 
Bronte et al. has described C/EBP-b as a critical factor for MDSC suppression 
(Marigo et al., 2010).  As C/EBP-b has been described as controlling emergency 
granulopoiesis (Hirai et al., 2006), we thought we would test whether this 
transcription factor was important for development of BM-IMC or if these cells 
require it for activation into BM-MDSC.  To answer this question we utilized C/EBP-
b fl/fl X VAV-Cre mice, which lack C/EBP-b in all cells, and assessed the result 
compared to their control mice, VAV-Cre, which have fully functional C/EBP-b, just 
expressing CRE under the VAV promoter.  The active VAV promoter, expressed in 
all cells, transcribes CRE recombinase, which then is able to cleave at the loxp sites 
surrounding the C/EBP-b gene.  In the case of the control mouse, the CRE 
recombinase has no loxp sites to cleave, therefore there is no removal of any gene.  
BM-IMC generated from these mice were used for assessment of the different MDSC 
cell subsets.  D3 BM-IMC had a decreased percentage of Ly-6ChighLy-6G- cells 
(mono-MDSC) by 35%, although not significant (p=0.081).  Interestingly, this change 
had very little influence, 10% reduction (p=0.1), on the percentage of Ly-6CloLy-6G+ 
cells (PMN-MDSC) yielded in the D3 culture of BM-IMC (Figure R3).  We 
investigated the role of C/EBP-b on activation, by culture of bulk BM-IMC in the 
presence of LPS/IFN-g overnight to assess the supernatants for the production of NO.  
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There was an observed significant decrease in the NO production  (Figure R3). 
Unfortunately, we cannot discount the lack of 35% of the mono-BM-MDSC subset 
contributing to the decrease.  Therefore, one must sort the populations and then test 
for NO to accurately analyze this activation. To characterize the splenic populations 
in vivo, we assessed whole splenocytes for MDSC markers.  Interestingly, the organs 
seemed comparable to the control mice (Figure R3C).  We conclude that BM-IMC, 
which arise during inflammation, require C/EBP-b for generation of mostly the 
generation of mono-MDSC, whereas the PMN-MDSC is slightly altered or unaffected.  
This lack of mono-MDSC generation most likely accounts for the decreased NO 
production, but as the reduction in NO was more than 35%, there seemingly may be 
further impairment of their activation.  This possible intrinsic defect needs to be 
investigated in further detail.  This effect in subsets is BM-IMC generation specific as 
the steady-state splenic MDSC subsets remain at comparable levels to their control 
counterparts.  We hypothesize this difference may be attributed to our growth factor, 
GM-CSF, occurring more in inflammatory conditions rather than during steady-state.  
Further changes in the ability of these in vivo populations after inflammation or 
infection would be interesting to analyze. 
 
 
 
Figure R3. BM-IMC require CAAT/enhancer binding protein-beta for differentiation and 
activation. A | D3 BM-IMC from mice lacking C/EBP-b (VAV-CRE X C/EBP-b fl/fl) and their 
controls (VAV-CRE) were generated in the presence of GM-CSF.  Percentage of subsets were 
compared by flow cytometry for MDSC markers CD11b, Ly-6C, and Ly-6G.  Results are from 3 
mice/group. Statistics was performed using a student T-test, p values did not reach significance.  B | D3 
BM-IMC from mice lacking C/EBP-b (VAV-CRE X C/EBP-b fl/fl) and their controls (VAV-CRE) 
were stimulated with LPS/IFN-g overnight.  Supernatants were analyzed via Griess Reagent for NO 
production. Results are from 3 mice/group. Statistics was performed using a student T-test.  P values 
are significant (p=0.005). C | Splenocytes from mice lacking C/EBP-b were analyzed by flow 
cytometry for MDSC makers CD11b, Ly-6C, and Ly-6G. Results are from 3 mice/group. Statistics was 
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performed using a student T-test.  P values did not reach significance.   
 
4.3 Induction of nitric oxide by bone marrow generated myeloid derived 
suppressor cells with various pathogens and interferon gamma requires MyD88, 
IFN-gR1, and IRF-1 signalling, but not activation by nucleic acids and self-
glycolipids. 
To understand if BM-MDSC activate in the presence of the autoimmune diseases 
microenviroment to become suppressive, we investigated activation of BM-MDSC by 
various compounds relating to EAE, including cytokines, pathogens, and glycolipids. 
The stimuli were selected based on their effects on DC to polarize T cells in different 
manners, i.e., Th1 or Th17.  A combination of LPS/IFN-g, polarizing in a Th1/CD8 
manner (Abbas AK, 2010; Re and Strominger, 2001), was previously elucidated to be 
a strong stimulator of BM-MDSC production of NO (Greifenberg et al., 2009), 
therefore we used this as a positive control.  To assess Th17-polarizing pathogens on 
BM-MDSC NO production, curdlan (Higashi et al., 2010) (a 1,3 beta-glycan purified 
from fungi), zymosan A (Veldhoen et al., 2006) (a yeast-derived 1,3 beta-glycan 
similar to curdlan but a more crude extract possibly contaminated with endotoxin), 
and an obvious choice as a component in CFA, heat-killed mycobacteria (Mtb) 
(Veldhoen et al., 2006; Zenaro et al., 2009), were selected. A link between NO 
production and EAE severity has been previously observed as iNOS deficient mice 
have more severe EAE.  We found that the three extracts from yeast, fungi, and 
bacteria can activate the MDSC to produce NO (Figure R4), therefore conclude that 
both Th1 and Th17-like polarizing stimuli can activate MDSC functionality.  
 
Figure R4.  Different bacterial, fungal, and yeast stimuli can induce bone marrow generated 
myeloid derived suppressor cell activation, whereas nucleic acids and self glycolipids cannot.  A | 
D3 C57Bl/6.BM- IMC were stimulated with different bacterial or fungal stimuli in the presence of T 
effector cell cytokines, IFN-g or IL-17, overnight or left unstimulated.  Supernatants were analyzed for 
NO production (Nitrites, µM).  Graph is representative of 3 independent experiments. B | D3 
C57Bl/6.BM-IMC were stimulated with nucleic acids, CpG and poly (I:C) or left unstimulated.  
Supernatants were analyzed for NO production.  C | D3 C57Bl/6.BM- IMC cultured in the presence of 
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GM-CSF were stimulated with self glycolipids or left unstimulated.  Supernatants were analyzed for 
NO production.  No significance was reached by student T-test. 
 
As LPS and IFN-g signals are known to activate BM-IMC in a synergistic manner, we 
wanted to investigate if similar effector cytokine-pathogen combination can stimulate 
BM-IMC under Th17 conditions.  Therefore, BM-IMC were stimulated using a 
combination of IL-17 with the pathogenic stimuli.  We did not see any increased NO 
production (Figure R4), whereas the NO production by all pathogens tested could be 
boosted by IFN-g (Figure R4). We conclude the combination of pathogen stimuli, 
such as LPS, curdlan, zymosan A, and mycobacteria, with IFN-g work in a synergistic 
effect to boost the suppressive capacity of BM-IMC into BM-MDSC through 
production of NO, whereas Th17 cytokines do not. 
 
Figure R5.  Different stimuli can induce nitric oxide production by BM-MDSC through MyD88, 
IFN-gR1, and partially through IRF-1 signalling. A | D3 BM-IMC from mice lacking TLR4 and 
MyD88 signalling molecules were stimulated with different pathogenic overnight or left unstimulated.  
Supernatants were analyzed for NO production.  B | D3 BM- IMC lacking IFN-gR1 were stimulated 
with different pathogenic overnight or left unstimulated.  Supernatants were analyzed for NO 
production.  C | D3 BM-IMC deficient in one (IRF-1+/-) or both alleles (IRF-1-/-) of IRF-1 were 
stimulated with LPS/IFN-g overnight or left unstimulated.  Supernatants were analyzed for NO 
production.  Results of two independent experiments were normalized to stimulated control IRF+/+ BM-
IMC.  Decrease reaches significance by student T-test. 
 
As some links have been associated between viral pathogens and inflammation to MS, 
therefore the question arises if viral pathogens or dead tissue can activate MDSC to 
become suppressive.  To analyze if viral nucleic acids or if loose nucleic acids which 
may become available during infection and inflammation by release of intracellular 
contents by dead or necrotic cells, may activate the MDSC (Barker et al., 1999; 
Gallucci et al., 1999; Sauter et al., 2000), stimulation with dsDNA, such as CpG, and 
dsRNA, such as poly (I:C) was performed.   In accompaniment with damaged myelin 
sheath, self glycolipids were observed within the CNS during active lesions in MS.  
To understand if this may activate MDSC, BM-IMC were stimulated with a small 
panel of self glycolipids.  Suprisingly, neither material from nucleic acids, nor self 
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glycolipids (Figure R4) could not activate the MDSC to produce NO.  We conclude 
that pathogens, but not cellular material alone could activate MDSC. 
 
As this boosting effect was only seen upon IFN-g administration, we wanted to 
identify the signalling mechanisms in MDSC to induce NO production.  Myeloid 
differentiation primary response gene (MyD88) has been shown to be required for 
activation of MDSC in vivo under septic conditions (Delano et al., 2007).  To 
investigate if Th17 stimuli activate BM-IMC iNOS through TLR-MyD88 signalling 
pathway or if they can alternatively signal through dectin-1, we performed 
experiments employing BM-IMC generated from TLR4-/- mice and TLR4-/- MyD88-/- 
mice.  Overnight treatment with of TLR4-/- mice and TLR4-/- MyD88-/- BM-IMC with 
pathogenic stimuli was performed and NO production was detected by Griess reagent.  
BM-IMC NO production in by all stimuli tested is induced through the MyD88-TLR 
pathway (Figure R5). The model has been proposed that MDSC require two signals, 
MyD88 and IFN-g signaling, that are required for activation of iNOS for subsequent 
suppressive function.  Therefore, we wanted to analyze the requirement of IFN-g 
signaling on the activation of BM-IMC.  To do this, we performed an experiment 
generating BM-IMC from IFN-gR1-/- mice.  BM-IMC were incubated overnight in the 
presence of bacterial stimuli and analyzed the NO production.  Without IFN-gR1, 
BM-IMC cannot produce NO (Figure R5).  Therefore, both the proposed multi-signal 
requirement for activation of iNOS by BM-IMC is validated.  To investigate 
downstream signaling leading to the activation of iNOS, experiments were performed 
with BM-IMC from one or both alleles of IRF-1 knockout were analyzed for NO 
production.  Upon activation with LPS / IFN-g, both IRF-1 knockout mice had 
equalivently reduced levels of NO production, roughly 30% (Figure R5).  Indicating 
IRF-1 has a limited role in induction of iNOS, but their must be other players 
involved in the downstream signalling. 
 
4.4 Interferon-beta, used in multiple sclerosis drug therapy, does not 
influence myeloid derived suppressor cell activation or suppressive capacity.  
Type I interferons play an important role in regulating disease severity.  MS patients 
receiving IFN-b reduces the severity of clinical symptoms.  Furthermore, Prinz et al. 
(Prinz et al., 2008) has demonstrated that IFN-aR deficient mice have stronger EAE 
disease severity correlating with a CD11b population.  Interestingly, IFN-a has been 
shown to block MDSC suppressive function in vivo (Zoglmeier et al., 2011).  
Therefore, we wanted to investigate the effects of poly (I:C), which have been 
determined to induce IFN-b production in other cell types, such as DC (Okahira et al., 
2005) and IFN-b itself directly on MDSC.  Therefore, to elucidate if IFN-b might 
activate or prevent activation of MDSC, BM-IMC were stimulated with IFN-b and 
poly (I:C) overnight in the presense or absence of the activating stimuli LPS/IFN-g.  
NO production was analyzed by Griess Reagent.  NO production was unaltered 
compared to the LPS/IFN-g treated BM-IMC, and IFN-b treatment alone was 
comparable to untreated BM-IMC (Figure R6).  We conclude IFN-b does not alter 
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BM-IMC activation to produce NO.  To discover if IFN-b may play a role in 
stimulating or inhibiting MDSC function through other mechanisms besides NO, the 
suppressive capacity in the presense of IFN-b was assessed.  No change in 
suppressive capacity was observed (Figure R6).  It is unknown if BM-MDSC 
themselves may produce sufficient amounts of IFN-a/b, which may cause this 
unaltered suppressive capacity upon the presence of exogenous IFN-b, as it possibly 
could already be at saturating levels.  BM-IMC activation by IFN-a or IFN-b through 
their receptor IFN-aR was tested using knockout mice. Suppressive capacity by NO 
production and a functional suppression assay both confirmed BM-MDSC 
functionality was unaltered (Figure R6C).  Therefore, we can conclude that IFN-b 
therapy may not directly influence the MDSC alone during treatment of MS, as BM-
IMC activation and suppressive capacity is unaltered in its presence. 
 
 
 
Figure R6. Bone marrow generated myeloid derived suppressor cell are not influenced by 
interferon-beta.  A | D3 C57Bl/6 BM-IMC were stimulated with IFN-b-1a, IFN-b-1b, or poly (I:C) in 
the presence or absence of LPS/IFN-g overnight or left unstimulated.  Supernatants were analyzed for 
NO production by Griess Reagent.  Student T-test was performed no statistical difference was found.  
Results based on 2 separate experiments, one representative experiment shown.  B | D3 BM-IMC from 
C57Bl/6 mouse were added to stimulated splenocytes in the presence or absense of IFN-b-1a and IFN-
b-1b.  Radioactive [3H] thymidine was used to assess proliferation.  No significant differences as 
performed by student T-test.  Results of two separate experiments. C | D3 BM-IMC from IFN-aR-/- 
mice were stimulated with IFN-b overnight or left unstimulated.  Supernatants were analyzed for NO 
production by Griess Reagent.  Student T-test was performed, no statistical difference was observed.  
Results based on 3 mice.  D | D3 BM-IMC from C57Bl/6.IFN-aR-/- or C57Bl/6.WT mice were added to 
C57Bl/6 splenocytes stimulated with anti-CD3/anti-CD28.  Radioactive [3H] thymidine was used to 
assess proliferation.  No statistical difference was observed by student T-test.  Results of 3 mice. 
 
4.5 Both in vitro generated and endogenous myeloid derived suppressor cells 
specifically upregulate B7-H1, but no change occurs in co-stimulatory markers 
on both subsets 24h after pathogen stimulation.  
To investigate potential cell-to-cell contact mechanisms BM-MDSC employ, analysis 
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of BM-MDSC surface expression was performed.  One would hypothesize, as BM-
IMC are suppressive, co-inhibitory markers rather than co-stimulatory markers would 
be expressed upon activation. Surface expression of MDSC after their activation by 
LPS, curdlan, zymosan was investigated by flow cytometry.  Gating was performed 
individually on each subset, Mono-MDSC (CD11b+/Ly-6C+) and PMN-MDSC 
(CD11b+Ly-6C+Ly-6G+).  Both populations upregulated the expression of B7-H1, but 
did not increase any co-stimulatory markers such as CD40, CD80, CD86, CD70, or 
tolerance markers B7-H2 (Figure R7). As BM-IMC upregulate B7-H1 upon 
stimulation, we checked the expression of this marker on endogenous splenic MDSC, 
to determine if similar things happen in vivo.  EAE induction was performed on day 0.  
After 24 h, spleens from both EAE and untreated mice were re-stimulated for 4 h with 
PMA/Iono.  MDSC populations were assessed by FACS for expression of B7-H1.  
During steady-state conditions, there is no B7-H1 expression on the splenic fraction 
of MDSC, but one day post EAE induction, increased B7-H1 expression and a 
downregulation of CD86 (Figure R8) was observed upon restimulation.  To 
understand if BM-IMC changes the balance by increasing the amount of B7-H1 in the 
system, spleens were examined according to the same protocol, but administering a 
BM-IMC injection three days prior to EAE induction.  In this case, splenocytes 
receiving BM-IMC had no differences (Figure R8) compared to their untreated 
controls in their expression of B7-H1 intensity on MDSC. 
 
Figure R7.  Phenotype of BM-MDSC from C57Bl/6 mouse.  D3 C57Bl/6.BM-IMC stimulated with 
LPS/IFN-g, curdlan, or zymosan overnight or left unstimulated (black).  Flow cytometry staining for 
activation markers gated upon MDSC subsets: CD11b+ Ly-6C+ Ly-6G+ or CD11b+ Ly-6C+ Ly-6G-, 
B7-H1, and PD-L2.  Isotype control is depicted in grey. Result of 3 independent experiments.  Results 
of one experiment shown. 
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Figure R8.  Phenotype of Endogenous MDSC from C57Bl/6 mouse after activation.  A | C57Bl/6 
mice were either induced with EAE (D0) or left untreated.  Splenocytes were restimulated on D1 ex 
vivo using PMA/Iono for 4 h.  Surface markers of MDSC were assessed as shown pre-gated on CD11b+ 
Ly-6C+ Ly-6G+ or CD11b+ Ly-6C+ Ly-6G-. Results of 2 independent experiments.  One experiment 
shown. B | C57Bl/6 mice were either induced with EAE (D0).  Spleens were restimulated on D1 for 4 h 
with PMA or LPS in the presence or absence of Iono, expression of B7-H1 on MDSC was assessed.  
Results of 2 independent experiments.  One experiment shown. C | Mice were injected with BM-IMC 
three days prior to induction of EAE (D0).  Spleens were restimulated on D1 for 4 h with PMA/Iono, 
B7-H1 expression of MDSC was assessed.  Results of 3 mice/group. 
 
4.6 Bone marrow generated immature myeloid cells injected into mice cause 
suppression of experimental autoimmune encephalomyeolitis induced by myelin 
oligodendrocyte glycoprotein35-55. 
To establish a possible role for MDSC as a cellular therapy in autoimmune diseases 
BM-IMC were injected D-3 before EAE injection to assess the ability to suppress the 
disease severity in vivo. Compared to WT controls, the clinical score of MDSC 
injected mice were lower (Figure R9).   On the peak day, day 14, mice were sacrificed 
and underwent further evaluation, including analysis of infiltrates in the CNS, 
including brain and spinal chord sections, and in the spleen.  Immune infiltrates were 
analyzed within the CNS and spleen (Figure R9) through intracellular cytokine 
analysis, and also the organs were placed embedded into OCT, a compound used for 
freezing your tissue, for immunofluorescence stainings. Further analysis revealed 
there were slightly increased infiltrates within the CNS from untreated as compared to 
MDSC injected mice WT-BM-IMC, while analysis of the spleens showed an 
increased overall cellularity from MDSC injected mice (Figure R9).  These infiltrates 
showed no change in the pathogenic cytokines, IFN-g and IL-17, in MDSC injected 
mice in neither the IL-17, nor the IFN-g after restimulation with PMA/Iono (Figure 
R10).  To evaluate the ability of BM-IMC to suppress EAE, various changes were 
performed to the protocol.  The evaluation of BM-IMC injected via various route was 
performed.  The protection between the two delivery methods (i.p. vs i.v.) showed 
comparable protection as compared to the EAE control group.  Next, we attempted to 
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assess whether pre-activated BM-MDSC for 4 h with LPS / IFN-g instead of 
untreated BM-IMC would protect more as BM-MDSC produce nitric oxide.  Pre-
activated BM-MDSC seemed to protect via a delay, but not in severity, we believe 
this intermediate interaction may due either to changes in integrins after activation 
causing a differential homing or due to the activated BM-MDSC secretes the NO 
before it reaches the location where BM-IMC suppress, where BM-IMC become 
activated and suppress. 
 
 
 
Figure R9.  Brain section of EAE mice show increased infiltrates 
A | Mice were allowed to develop clinical symptoms until the peak of the disease (day 14), then mice 
were sacrificed, the B | spleen and C | CNS were removed, lymphocytes were isolated by collagenase 
NB4 and DNase I digestion and overlayed on a percoll gradient and cell numbers were assessed. Mice 
were allowed to develop clinical symptoms until the peak of the disease (day 14), then mice were 
sacrificed, CNS were removed and counted.  Significant differences, as performed by student T test, 
between control untreated EAE and BM-IMC treated EAE mice were obsesrved at later time points 
Days 12 – 14, p<0.05. 
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Figure R10.  Bone marrow generated immature myeloid cells may slightly protect EAE mice.  
A / B | Mice were induced with EAE.  At the peak of the disease (day 14) mice were sacrificed and 
spleens were restimulated with PMA/Iono in the presence of brefeldin A for 4h.  ICC was performed to 
assess the amount of IFN-g (A) and IL-17 (B) production in CD4 cells. Significant was assessed by 
student T test.  This is one representative experiment of 2. C / D | Mice were induced with EAE.  At the 
peak of the disease (day 14) mice were sacrificed CNS isolated.  Digestion was performed with 
collagenase NB4 and DNase I digestion and overlayed on a percoll gradient.  Cells were restimulated 
for 4 h with PMA/Iono and brefeldin A. IFN-g (C) and IL-17 (D) production was examined by 
intracellular cytokine staining.  
 
Figure R11.  Bone marrow generated immature myeloid cells slightly protect and/or delay onset 
of EAE in mice without regard to route of administration, but may be affected by activation 
status and timing. 
A | C57Bl/6 mice were injected with BM-IMC/PBS (i.v. or i.p.; Day -3) then MOG- EAE was induced 
(Day 0, 2). Clinical Score was assessed (3mice/group). A significant delay was observed, significance 
analyzed by day using student T-test. B | C57Bl/6 mice were injected with BM-IMC or BM-IMC 
stimulated 4h with LPS/IFN-g (i.v.; Day -3) then MOG-EAE was induced (Day 0, 2). Clinical Score 
was assessed (3 mice/group). A significant delay was observed, significance analyzed by day using 
C
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.0 
U
nt
re
at
ed
 
W
T.
IM
C
 
B
7H
1-
/- 
IM
C
 
Pe
rc
en
t I
L
17
+ 
pr
od
uc
er
s a
m
on
g 
 C
D
4+
 C
N
S 
 in
fil
tr
at
es
  
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
U
nt
re
at
ed
 
W
T.
IM
C
 
B
7H
1-
/- 
IM
C
 
Pe
rc
en
t I
FN
g+
 p
ro
du
ct
er
s a
m
on
g 
 
C
D
4+
 C
N
S 
in
fli
ra
te
s 
D#
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
U
nt
re
at
ed
 
W
T.
IM
C
 
B
7H
1K
O
.IM
C
 
Pe
rc
en
t C
D
4+
IF
N
g+
  
pr
od
uc
er
s i
n 
th
e 
Sp
le
en
 
A#
0.00 
0.01 
0.02 
0.03 
0.04 
0.05 
U
nt
re
at
ed
 
W
T.
IM
C
 
B
7H
1K
O
.IM
C
 
To
ta
l C
D
4+
 IL
-1
7+
 p
ro
du
ce
rs
  
in
 th
e 
Sp
le
en
 
B
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.0 
D
0 
D
4 
D
8 
D
9 
D
10 
D
11 
D
12 
D
13 
D
14 
D
15 
C
lin
ic
al
 S
co
re
 
Days post induction 
Untreated EAE 
IMC iv 
IMC ip 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
3.5 
4.0 
4.5 
5.0 
D
0 
D
2 
D
5 
D
6 
D
7 
D
8 
D
9 
D
10 
D
11 
D
12 
D
13 
D
14 
D
15 
C
lin
ic
al
 S
co
re
 
Days post induction 
Untreated EAE 
Untreated WT.IMC 
LPS/IFNg 4h WT.IMC 
A B 
C 
0.0#
1.0#
2.0#
3.0#
4.0#
5.0#
D0#
D4#
D7#
D8#
D9#
D10#
D11#
D12#
D13#
D14#
D15#
Cl
in
ic
al
'S
co
re
'
Days'post'induc3on'
Untreated#
WT.IMC#(D:3)#
WT.IMC#(D+3)#
SANDWICK DOCTORAL THESIS, JUNE 2012! RESULTS 
 
P a g e | 56  
 
student T-test. C | C57Bl/6 mice were injected with BM-IMC (iv; Day -3, Day +3) then MOG-EAE 
was induced (Day 0, 2). Clinical Score was assessed. A significant delay and decreased severity was 
observed with our Day -3 cells (3 mice), but earlier onset was observed upon IMC treatment on Day+3 
(7 mice) Significance analyzed by day using student T-test. 
 
4.7 Increased suppression of specific memory cells by bone marrow 
generated immature myeloid cells is dependent upon the expression of PD-1 on 
splenocytes in vitro. 
To test the ability of MDSC suppression by the B7-H1 : PD-1 interaction, analysis of 
naïve T cells was performed by a suppression assay utilizing B7-H1 deficient BM-
IMC (Figure R12) with OTII specific T cells. No difference in suppressive capacity 
was observed.  Similar results were also observed upon stimulation of allogeneic 
(Balb/c) splenocytes stimulated with antibody (data not shown).  As PD-1 
functionality has been described in the phenotype of cells during chronic diseases and 
infections, a suppression assay utilizing memory cells was performed.  PD1-/- and 
wildtype splenocytes were taken at the peak of EAE and restimulated specifically or 
aspecifically with antibodies, suppression by BM-IMC was assessed.  There were no 
significant differences seen between the groups (Figure R12).  C57Bl/6 mice induced 
with MOG-EAE were sacrificed on day 14, spleens were re-stimulated with MOG 
peptide.  BM-IMC stained with Ly-6G-biotin, followed by the addition of streptavidin 
microbeads.  MACS separation was performed to obtain PMN-MDSC and Mono-
MDSC subsets.  These subsets were fixed for 30 minutes to allow assessment of only 
surface cell-cell contact mediated interactions.  To fully assure our fixative did not 
alter the proliferating T cells, cells were incubated in media overnight.  These fixed-
MACS-sorted D3-BM-IMC subsets from C57Bl/6.WT or C57Bl/6.B7-H1-/- mice 
were added to the restimulated splenocytes.  Proliferation was assessed by radioactive 
[3H] thymidine.  Proliferation showed lack of B7-H1 releases BM-IMC regulation on 
antigen specific T cells (Figure R13). 
 
 
Figure R12.  Bone marrow generated immature myeloid cells suppress T cells with no influence 
of PD-1 
A | C57Bl/6 (filled) and B7-H1 knockout (open) BM-IMC were titred into OVAII peptide (1uM) 
stimulated OTII splenocytes. Cells were pulsed with radioactive [3H] thymidine to assess proliferation. 
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Results of 2 experiments are shown.  Statistics was performed using a student T-test.  P values were not 
of significance.  B | C57Bl/6 and PD-1 knockout mice were induced with EAE (Day 0, 2).  At the peak 
(day 14), splenocytes restimulated specifically with MOG peptide (left) and aspecifically using 
aCD3/aCD28 (right), in the presence of BM-IMC.   Cells were pulsed with radioactive [3H] thymidine 
to assess proliferation. Results of 3 mice are shown.  Statistics was performed using a student T-test.  P 
values were not of significance. 
 
 
 
Figure R13.  Bone marrow generated immature myeloid cells suppress memory cells more than 
effector cells through interaction between B7-H1 and PD-1 
A | C57Bl/6 mice were induced with EAE (Day 0, 2).  At the peak (day 14), splenocytes restimulated 
specifically using MOG peptide, in the presence of fixed-MACS-Sorted Ly-6G+ and Ly-6G- subsets 
from BM-IMC of either B7-H1 deficient or compentent mice.   Cells were pulsed with radioactive [3H] 
thymidine to assess proliferation. Results of 3 mice are shown.  Statistics was performed using a 
student T-test.  Significant differences were found between the B7-H1 knockout and wildtype BM-
IMC (p<0.05).  A trend was observed for the Ly-6G+ subset, but p values were not all of significance.   
B | C57Bl/6 mice were induced with EAE (Day 0, 2) and allowed to develop disease until the peak 
(day 14).  Splenocytes restimulated aspecifically using anti-CD3/anti-CD28 peptide, in the presence of 
fixed-MACS-sorted Ly-6G- subsets from BM-IMC of either B7-H1 deficient or compentent mice. 
Results of 3 mice are shown.  Cells were pulsed with radioactive [3H] thymidine to assess proliferation.   
Statistics was performed using a student T-test.  P values were not of significance. 
 
4.8 Bone marrow generated immature myeloid cells expression of B7-H1 does 
not change the ability to suppress experimental autoimmune encephalomyelitis 
severity, but PD-1 expression in recipient mice does. 
As MDSC increase expression of B7-H1 upon activation was already demonstrated 
both in vitro and in vivo and B7-H1 expression was required for regulation of memory 
cell proliferation in vitro, assessment of the B7-H1 : PD-1 interaction in vivo still 
needed to be elucidated. To confirm this interaction C57Bl/6 and C57Bl/6.B7-H1-/- 
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BM-IMC were injected into mice (iv; Day -3), followed by EAE induction (Day 0, 2).  
Clinical Score was assessed.  This allowed for protection by both groups (Figure R14).  
Although B7-H1 on BM.IMC seemingly does not play a role in the suppression of 
EAE, confirmation was performed utilizing splenocytes from PD-1-/- mice.  Injection 
of BM-IMC into C57Bl/6 or C57Bl/6.PD-1-/- mice (iv; Day -3), EAE (Day 0, 2) 
induced, and Clinical Score was assessed.  Demonstrating protection only in C57Bl/6 
mice, indicates a role of MDSC suppression of EAE via interaction with PD-1 (Figure 
R14).  
 
Figure R14.  Direct or indirect interaction with PD-1 may play a role in BM-IMC suppression in 
vivo, whereas B7-H1 expression itself upon the BM-IMC does not influence protective capacity in 
EAE.   
A | C57Bl/6 mice were injected with B7-H1-/- or WT BM-IMC/PBS (iv; Day -3) then MOG- EAE was 
induced (Day 0, 2). Clinical Score was assessed. Significant decrease in severity was observed in both 
groups.  Statistical analysis was performed by student T-test.  B | C57Bl/6 or C57Bl/6.PD-1-/- mice 
were injected with C57Bl/6 BM-IMC/PBS (iv; Day -3) then MOG-EAE was induced (Day 0, 2). 
Clinical Score was assessed.  No difference between the groups was observed by student T-test. 
 
4.9 Kinetics of bone marrow generated immature myeloid cells accumulate in 
the spleen, homing to the  red pulp and marginal zones. 
To identify BM-IMC migration and localization in vivo after intravenous injection, 
bioluminescence imaging (BLI) techniques were employed.  To utilize this technique, 
BM-IMC can be generated from mice containing a vector encoding for the enzyme 
luciferase.  In the presence of luciferin, luciferase will cleave the luciferin into 
products emitting photons (luminescence).  The detection of photon emission can be 
detected using a special camera system, allowing daily assessment of migration and 
localization of the injected BM-IMC within the same mouse.  BLI, a safer method as 
compared to radioactive labeling, has the advantage of one detecting only live cells, 
however the method itself lacks some sensitivity.  If cells are in low quantities and/or 
diluted over the whole body, detection is not possible.  As BM-IMC may not 
proliferate after injection, increased amounts of BM-IMC were injected to allow for 
proper detection.  As black hair may absorb some signal, C57Bl/6.albino mice were 
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used as recipients.  To understand BM-IMC localization of BM-IMC in steady-state 
mice, mice were injected with Luc+BM-IMC.  After 24h, BM-IMC were 
anaesthesized, luciferin was injected observed in the lungs and spleen ex vivo (Figure 
R15).  To understand their homing during steady-state or inflammatory, kinetics of 
Luc+BM-IMC migration in untreated and EAE mice were assessed daily subsequent 
to the injection of BM-IMC.  It was observed that BM-IMC accumulate in the spleen 
during steady-state conditions, whereas during inflammation, the cells are not only 
recruited to the spleen but also recruited to the site of inflammation (the subcutaneous 
injection of CFA) and to the site draining the inflammed immune priviledged organ, 
the cervical lymphnode (Figure R16).  To understand if BM-IMC can actively home 
from tissue to the spleen, BM-IMC subsets were inject sc in the footpad.  Migration 
was analyzed, determining BM-IMC travel to the draining lymph node (Figure 17).  
We speculate BM-IMC cannot exit or possibly may differentiate into resident lymph 
node cells.  
 
 
  
Figure R15.  Imaging shows bone marrow generated immature myeloid cells accumulate mostly 
in lungs and spleen after 24h 
C57Bl/6.albino mice were injected with Luc+BM-IMC 24h after i.v. administration in vivo and ex vivo 
imaging was performed upon injection of luciferin.  Data representative of 3 separate mice, one mouse 
in vivo and ex vivo image depicted.  Analysis performed on 3 separate mice ex vivo organs was 
performed.  Lumenescence quantified per organ as photons detected/second.   
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Figure R16.  Imaging depicting kinetics of BM-IMC migration in vivo, suggests bone marrow 
generated immature myeloid cells accumulate in spleen after 4 days. 
C57Bl/6 albino mice were injected with Luc+ BM-IMC.  BLI imaging was performed daily upon 
injection of luciferin.  Mice with low grade EAE (score 2; tail paralysis) were also injected and imaged. 
Data displayed of one mouse, but representative distributation of several mice. 
 
 
Figure R17.  Imaging illustrates in addition to spleen, bone marrow generated immature myeloid 
cells seemingly are recruited to CFA/MOG injection site and draining lymph nodes. 
A | C57Bl/6 albino mice were injected s.c. in one foot pad with FACS-Sorted Luc+ mono-BM-IMC 
and PMN-BM-IMC or bulk.  BLI imaging was performed 24h after injection. Data representative of 
two experiments, one mouse depicted. 
 
To attempt to quantify the BM-IMC and characterize BM-IMC, ex vivo analysis of the 
organ was performed.  BM-IMC labeled with CM-DiI, a dye which labels membranes, 
were injected i.v. into C57Bl/6 mice.  After 4 days, a single cell spleens suspension 
was lysed of RBC.  A white collagenous “blob” arises within the cell suspension.  
This “blob” was placed on a microscope slide for analysis.  As seemingly all CM-DiI 
BM-IMC were found within this “blob,” no cells were discovered via flow cytometry 
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for PE (Figure R18).  To understand BM-IMC localizing within the spleen, 
fluorescence microscopy was employed. CM-DiI BM-IMC injected i.v. into C57Bl/6 
mice were allowed to migrate in vivo for 4 days, thereafter spleens were fresh frozen 
for cryosection analysis.   CM-DiI BM-IMC were seeming located within the 
marginal zone and red pulp areas of the spleen, but not in the white pulp (Figure 18). 
 
 
Figure R18.  Imaging shows bone marrow generated immature myeloid cells accumulate in 
spleen after 4 days, localizing to outside the white pulp. 
A | C57Bl/6 mice were injected with CM-DiI labelled BM-IMC.  On day 4, spleen was digested and 
lysed. A white “blob” structure was observed within the single cell suspension was placed onto a 
microscope slide and analysed for PE fluorescence.   B | C57Bl/6 mice were injected with CFSE 
labelled BM-IMC.  After 4 days, spleens were removed and fresh frozen in OCT.  Staining was 
performed using CD169.  Sections were analyzed for CM-DiI BM-IMC (Swirski et al.) and CD169 
(Green), localization seems restricted to outside the white pulp. 
 
4.10 Bone marrow generated immature myeloid cells induce increased spleen 
cellularity by induction of proliferation of splenic cells. 
BM-IMC localize in the spleen, but their mechanism of action to suppress was still 
unclear. Therefore, to investigate this mechanism BM-IMC were injected i.v. into 
C57Bl/6 mice.  After 4 days, mice were induced with EAE.  On day 7 after induction, 
spleens were removed and counted. We found an increase of cell numbers within the 
spleen (Figure R19).  As PD1-/- mice were not protected, we analyzed the spleen 
counts.  There were no differences observed between BM-IMC injected and untreated 
EAE spleens in PD-1 deficient recipient mice (Figure 19), indicating that the increase 
observe may cause protection.   Further assessment of the B7-H1 interaction with PD-
1 as a possible role in the increases in spleen cellularity was performed as BM-IMC 
from mice lacking B7-H1 or WT were injected into EAE mice on Day 5 after 
induction and assessed the spleens at day 9. No differences between the WT-BM-IMC 
and the B7-H1-/- BM-IMC in comparison to spleen size (Figure 19) were observed.  
As BM-IMC delivered after EAE were not protective, it might suggest protection is 
correlated to timing or the locality of particular cells in which BM-IMC interact. 
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Figure R19.  Increased spleen cellularity in wildtype, but not program death receptor 1 knockout 
mice injected with bone marrow generated immature myeloid cells.  
A | C57Bl/6 mice were injected with BM-IMC (D-4), followed by induction of EAE (D0, D2), spleens 
were removed and counted.  Cell numbers were normalized to the control EAE spleen.  Statistics was 
performed using a student T-test. B |  C57Bl/6 and C57Bl/6.PD-1-/- mice were injected with BM-IMC 
(D-4), followed by induction of EAE (D0, D2).  Day 7 after EAE induction, spleens were removed and 
counted. Cell numbers were normalized to the control EAE spleen.  Statistics was performed using a 
student T-test. C | C57Bl/6 mice were induced with EAE (D0, D2).  Mice were subsequently injected 
with BM-IMC from C57Bl/6.B7-H1-/- or C57Bl/6 mice (D+5), Day 9 after EAE induction, spleens 
were removed and counted. Statistics was performed using a student T-test.   
 
In vitro, we noticed the effect of MDSC to induce proliferation (Figure R20) upon 
interaction of MDSC with resting T cells in the presence of a superantigen, 
staphylococcus enterotoxin B (SEB).  This superantigen would force the interaction of 
the MHCII molecule of the MDSC to interact with the TCR of the T cell without 
antigen.  Steady-state spleens should not have many activated T cells to suppress, and 
steady-state spleens are known not to have suppressive MDSC functionality, 
suggesting the effects of protection are more that of delivery of a tonic signal.  To 
determine if the spleens are bigger because BM-IMC induces proliferation of cells 
within the spleen, BM-IMC were injected i.v. into mice.  After 4 days, spleens were 
harvested, labelled with CFSE and placed in culture for 6 days unstimulated. 
Proliferation was assessed via flow cytometry.  We found an increase of cell 
proliferation in CD11b, B220, CD4, and CD8 cells (Figure R21).  Upon further 
analysis of the proliferating subsets of CD4, we found an increase in proliferation of 
CD4 T regulatory cells, as compared to CD4 effector cells (Figure R22).   
 
To confirm this “tonic” signal by BM-IMC after injection instead of some activated 
function caused by soluble mediators, such as Arg-1 and NO, we compared EAE 
spleens to that of BM-IMC injected EAE spleens for the expression levels of Arg-1 
(Figure 23).  We found significant increases in the relative expression level.  To 
analyze BM-IMC directly or indirectly effected the recruitment or proliferation, BM-
C. C. B. A. 
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IMC lacking one of the signals controlling activation and subsequent effector function 
in vitro, IFN-gR1, or the effector function itself, iNOS, were knocked out. No size 
changes occurred between the size of the spleens in these groups and they displayed 
similar proliferation results to that of WT BM-IMC (Figure R24).  
 
  
 
Figure R20.  Bone marrow generated immature myeloid cells induce proliferation in 
unstimulated synergistic T cells upon addition of superantigen.   
A | Spleens of untreated C57Bl/6 mice were stimulated with anti-CD3/anti-CD28 in the presence of 
SEB.  BM-IMC were titred into the wells to assess suppressive capactiy.  After 2 days, cells were 
pulsed with radioactive [3H] thymidine overnight, proliferation was assessed.  Results of two 
independent experiments, one shown.  Statistical analysis by student T-test show no significant 
differences between the groups. B | Spleens of untreated C57Bl/6 mice were stimulated with SEB in 
the presence of BM-IMC.  Wells were also seeded with only splenocytes without SEB as controls 
(labeled T cells in graph).  After 2 days, cells were pulsed with radioactive [3H] thymidine overnight, 
proliferation was assessed.  Significant increases from control T cells were observed with increasing 
concentrations of MDSC.  C | Splenocytes from OTII transgenic animals were activated by various 
concentrations of OVA protein to assess the ability of MDSC to process and present antigen to 
suppress specifically.  No significant differences could be detected by student T test.  D | Splenocytes 
from OTII transgenic animals were activated by various concentrations of OVAII peptide to assess the 
ability of MDSC to suppress specifically.  No significant differences could be detected by student T 
test. 
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Figure R21.  Proliferation of splenic cell subsets induced by injection of immature myeloid cells. 
A | C57Bl/6 mice were injected with BM-IMC (D-4), followed by induction of EAE (D0, D2), spleens 
were removed and counted.  B |  C57Bl/6 and C57Bl/6.PD-1-/- mice were injected with BM-IMC (D-4), 
followed by induction of EAE (D0, D2).  Day 7 after EAE induction, spleens were removed and 
counted. C | C57Bl/6 mice were induced with EAE (D0, D2).  Mice were subsequently injected with 
BM-IMC from C57Bl/6.B7-H1-/- or C57Bl/6 mice (D+5), Day 9 after EAE induction, spleens were 
removed and counted. D |  C57Bl/6 were injected with C57Bl/6.IFN-gR1-/-, C57Bl/6.iNOS-/- or 
C57Bl/6 BM-IMC (D-4), were injected i.v. into C57Bl/6 mice.  After 4 days, spleens were harvested, 
RBC were lysed with Gey’s solution, labelled with CFSE and placed in culture for 6 days unstimulated. 
Proliferation was assessed via flow cytometry for CD11b, B220, CD4, and CD8 cells.   
 
Figure R22. Bone marrow generated immature myeloid cells induce increased Foxp3 
proliferation relative to T effector cells ex vivo. 
A | BM-IMC were injected i.v. into C57Bl/6 mice.  After 4 days, spleens were harvested, RBC were 
lysed with Gey’s solution, labelled with CFSE and placed in culture for 6 days unstimulated. BM-IMC 
injected EAE mice (red, blue), un-injected EAE mice (grey), and in vitro stimulated with aCD3/anti-
CD28 stimulated (dashed) proliferation of effector and regulatory T cells was assessed via flow 
cytometry. Data are representative of several experiments.  One representative plot is depicted. 
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Figure R23. Relative arginase-1 expression is significantly increased in the spleens of EAE pre 
injected with bone marrow generated immature myeloid cells as compared to control EAE 
spleens. 
BM-IMC were injected i.v. into C57Bl/6 mice.  After 4 days, EAE was induced.  7 days after EAE 
inductions spleens were taken, RBC were lysed with Gey’s solution, qRT-PCR was performed.  Data is 
representative of 4 mice (EAE) and 7 mice (EAE+IMC).  Statistical significance obtained by student T-
test. 
 
 
Figure R24. Bone marrow generated immature myeloid cells proliferative function is unaltered 
by iNOS or IFN-gR1 indicating their activation of NO is not required for their effects. 
A | C57Bl/6 were injected with C57Bl/6.IFN-gR1-/-, C57Bl/6.iNOS-/- or C57Bl/6 BM-IMC (D-4), were 
injected i.v. into C57Bl/6 mice.  After 4 days, spleens were harvested, RBC were lysed with Gey’s 
solution, labelled with CFSE and placed in culture for 6 days unstimulated. Cells were gated on CD11b, 
B220, CD4, and CD8 for the different major cell types.  Percentage of the cell types was calculated.  B 
| C57Bl/6 were injected with C57Bl/6.IFN-gR1-/-, C57Bl/6.iNOS-/- or C57Bl/6 BM-IMC (D-4), were 
injected i.v. into C57Bl/6 mice.  After 4 days, spleens were harvested, RBC were lysed with Gey’s 
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solution, labelled with CFSE and placed in culture for 6 days unstimulated. Proliferation was assessed 
via flow cytometry for Ki67 postive cells with the different cell populations (CD11b, B220, CD4, and 
CD8).  
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5 Discussion 
 
As autoimmune diseases are very dehabilitating and the opportunity of cellular 
therapies is a viable option, we asked the question: Can MDSC cure EAE?  Within 
this thesis we display evidence that BM-IMC can be administered as a preventive 
therapy for EAE, which hopefully may be translatable to other autoimmune disease 
therapies as well, in the future.  The data displayed in the thesis suggests this partial 
protection are mediated by a non-specific stimulation of seemingly all cells within the 
spleen through soluble mediators amd possibly signaling through PD-1. 
 
5.1 Establishing the model of Cellular therapy by MDSC in EAE 
Utilizing in vitro generated BM-IMC we attempted to clarify the potential of MDSC 
as a cellular therapy for the cure of EAE. EAE was selected based on its ability to be 
induced, rather than a spontaneous model, because it allows us to assess our cells at 
specific time points within the disease. 
 
As a proof of concept, generation of BM-IMC in vitro reported by Rossner et al. 
(Rossner et al., 2005) was established in order to yield enough MDSC for cellular 
therapy.  As expected this protocol yielded the same phenotype of BM-MDSC with 
suppressive function and ability to produce NO (Figure R2) as previously described.  
To establish EAE, the dose of EAE (CFA/MOG and pertussis toxin) from Brandl et al. 
(Brandl et al., 2010) was adjusted to better suit our current mouse facility, as 
commensal bacteria play a role in generating the EAE severity (Lee, 2011)(Ochoa-
Reparaz et al., 2009) (Savidge, 2007).  Once the EAE was optimal and BM-IMC 
generated, BM-IMC as a cellular therapy in EAE was pursued.  To confirm BM-IMC 
could protect from EAE disease severity, an administration similar to that of the 
previously established protective semi-mature DC injection (Menges et al., 2002) was 
selected.  To begin BM-IMC was administered only once, already providing partial 
protection.  Mice receiving BM-IMC had a reduced clinical severity.  Interestingly, 
our protection ranged from a delay, a reduction or both.  Most commonly, we would 
find the reduction.  During the course of the thesis the average disease score during 
each individual experiment ranged in severity for the control mice without changes in 
the dose, therefore we hypothesize this unknown factor, which may contribute in 
controling the EAE severity alone may also influence BM-IMC suppressive capacity 
as well.  As EAE is driven by the Th1 and Th17 effector subsets, we investigated if 
suppression is mediated by suppression of Th1, which had been reported previously in 
tumor models, or if suppression of Th17 occurs in addition.  To answer the questions 
about their protective effect, a detailed analysis of factors which influence BM-IMC 
to become suppressive was performed. 
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5.2 Transcriptional factors in MDSC development and activation 
C/EBP-b has been described as a transcription factor for the generation of activated 
MDSC. To clarify if C/EBP-b plays a role in the differentation or the activation, we 
assessed cells from mice lacking the gene for C/EBP-b, in attempt to analyze the 
effects on BM-IMC generation and BM-MDSC activation separately. Although 
neither decrease is of significant (p=0.1), a 35% and 10% decrease in the generation 
of mono-MDSC and PMN-MDSC was observed respectively. To truly validate this 
observed trend, one must repeat with more mice. As C/EBP-b reportedly influences 
IL-6 signalling (Screpanti et al., 1995), and IL-6 may play a role in generation of 
MDSC (Bunt et al., 2007), together they might elucidate why a slight trend in 
decreased mono-MDSC generation is observed.   Most likely, as this decrease is not 
significantly significant, the development in our system from BM precursors to BM-
IMC (a steady-state condition) suggests generation may be more regulated by C/EBP-
a, as C/EBP-b has been described as required only for “emergency” granulopoiesis 
(Hirai et al., 2006).  “Emergency” granulopoesis is the accelerated generation of the 
neutrophils occurring in times of infection and inflammation, usually leading to 
neutorophilia (Panopoulos and Watowich, 2008). It has been noted that C/EBP-b 
deficient mice retain all normal hematopoietic cells and normal granulopoeisis (Hirai 
et al., 2006; Screpanti et al., 1995). This steady-state development is only blocked 
upon addition of activating signals, i.e., LPS/IFN-g.  This theory was contradicted by 
Koeffler et al., which noted neutrophils from C/EBP-b deficient mice do not respond 
normally to GM-CSF or G-CSF growth factors, enhancing their apoptosis (Akagi et 
al., 2008). Also, it has been shown that C/EBP-b can compensate for lack of C/EBP-a, 
so it is possible that the inverse compensation in our system can occur equally. 
Interestingly, others have shown that C/EBP-b is not required for the generation of 
precursors, but rather the re-pooling of the granulocytes after the neutropenia (Cain et 
al., 2011).   
 
The other question, does the activation of BM-IMC require C/EBP-b, was 
investigated by a functional assay.  The activation of BM-IMC with LPS/IFN-g was 
subsequent analyzed for NO production.  There was a significant decrease in the 
production of NO, but one cannot exclude decreased populations of mono-IMC, the 
major producers of NO within the culture, did not influence this production.  To gain 
better understanding into if these cells require C/EBP-b for activation, one must sort 
these cells first before assessing the NO production.  It has been shown mesenchymal 
stem cells utilize C/EBP-b for induction of iNOS (Xu et al., 2009).  Interestingly, it 
has been shown that IL-1b, but not IFN-g, nor IFN-g downstream signalling 
molecules, STAT-1 and IRF-1, is required for C/EBP-b activation of iNOS (Teng et 
al., 2002). To understand if the PMN-MDSC function was affected, we should also 
further investigate our BM-IMC for Arg-1 upon activation, although it already has 
been reported that in macrophages IL-4 signalling through C/EBP-b mediates Arg-1 
(Gray et al., 2005). The functionality of MDSC seemingly requires C/EBP-b as both 
effector function enzymes, iNOS (Eberhardt et al., 1998) and Arg-1 (El Kasmi et al., 
2008), are under its regulation.  Therefore we conclude in our system that C/EBP-b is 
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partially involved in generation of mono-MDSC, and to a lesser extent the 
generataion of PMN-MDSC.  The activation of the cells may also be influenced, but 
further testing is required.    
 
5.3 Activation requirements of BM-IMC by Th1 and Th17 microenviroment 
stimuli, in vitro 
To investigate the effect of stimuli and signals MDSC may encounter during EAE, 
incubation of various stimuli with BM-IMC and analysis of activation was performed. 
To study the effects of various factors on BM-IMC, NO detection was established as a 
high-throughput fashion to assess whether different stimuli can activate mono-BM-
IMC.  Griess reaction has been previously described to detect NO through a 
colormetric assay though detection of NaNO2 (end product) (Griess, 1879).  This test 
can be utilized as a characterization tool to assess whether the stimuli can or cannot 
activate MDSC with LPS/IFN-g, a known activator (Greifenberg et al., 2009), 
employed as the positive control. Pathogenic stimuli from bacteria, fungi, and yeast 
were able to activate BM-IMC. This activation was enhanced by IFN-g, but not IL-17.  
This activation of iNOS is dependent on IFN-gR1 and MyD88 signalling and occurs 
partially through IRF-1 signalling.  This mechanism has been described in suppressive 
monocytes in a transplantation model, identifying signaling through a IFN-gR-, IRF-
1-, STAT-1-dependent release of NO via iNOS (Garcia et al., 2010).  Alternatively 
other potential stimuli found during these inflammatory conditions, such as nucleic 
acid and self glycolipids do not activate BM-IMC, at least not functionally by 
inducing iNOS.    
 
Screening of various pathogenic stimuli with known capabilities to produce different 
effector cytokines in T cells upon stimulation by DC.  All of the pathogens assessed, 
from both bacterial, LPS and Mtb, and fungal/yeast origin, zymosan and curdlan, 
activated MDSC to produce NO.  We could show that zymosan, curdlan, and heat-
killed mycobacteria (H37RA), with their known signalling through either dectin 
and/or TLR2, can induce NO to the same capacity as LPS/IFN-g require MyD88 
signalling (in this case, through TLR2) only.  It has been found that MyD88 co-
signalling with Syk pathways in MDSC has been shown to lead to release of other 
suppressive or regulatory factors, such as IL-10 (Zhang et al., 2009).  Cell wall 
components such as LPS, curdlan, and zymosan have been reported to activate other 
myeloid cells, such as DC and macrophages (Kataoka et al., 2002).  Although it has 
been reported live Mtb inhibit iNOS (Miller et al., 2004), this is an active process, 
therefore heat-killed Mtb is unable to actively prevent the co-localization with the 
phagosomes subsequently allowing the observed NO production.  Therefore, Th17-
like inducing stimuli may also employ NO in MDSC to suppress T cell responses in a 
similar manner to that of Th-1 stimuli.  
 
Interestingly, NO has been described to regulate Th17 cells by decreasing IL-23R 
expression and decreasing their subsequent proliferation, but interestingly not 
affecting their induction (Niedbala et al., 2011), suggesting NO might work as a 
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negative feedback mechanism.  These reports, together with reports that zymosan-
induced EAE disease severity is transient, linked to reduced cytokines levels related 
to both induction (TGF-b, IL-6) and sustainance (IL-23) of Th17 as compared to Mtb-
induced EAE (Veldhoen et al., 2006), suggests a link between the increased Th17 
induction NO further downregulates Th17 cytokines.  This idea is supported by the 
observed increase of NO production by MDSC when stimulated with zymosan 
compared to Mtb.  
 
MS has been characterized by increased numbers of T cells with reactivity to 
glycolipids (Shamshiev et al., 1999).  Self glycolipids can be a source of autoimmune 
diseases through molecular mimicry of self tissues by bacterial pathogens, e.g. 
Borrelia burgdorferi (Martin et al., 2001), or viral pathogens, e.g. human herpes virus 
6 (Tejada-Simon et al., 2003) and Epstein Barr virus (Holmoy et al., 2004; Lang et al., 
2002; Wucherpfennig and Strominger, 1995), or induced by reactive oxygen species 
alteration of self, which is then recognized as foreign to the host.  Interestingly, 
biophysical studies have revealed affinity for the sequence of some microbial peptides 
is lower than that of the same sequence in auto-antigen peptides (Harkiolaki et al., 
2009).  In our studies, self glycolipids (ceramide, cerebroside, asialoGM-1, GM-1, 
ganglioside, sphingomyelin, and sulfatides) themselves were not stimulatory, as 
shown by equilvalent NO production to untreated controls. Self glycolipids also did 
not have an effect on the suppressive capacity.  This may be explained as 
sphingomyelin has been shown not to be able to activate NF-kB (Sun et al., 2010), but 
as other glycolipids, such as sulfatides, can induce activation of NF-kB (Jeon et al., 
2008).  This activation through NF-kB might not have a huge impact as other signals 
might be required in addition.  Further studies will have to be performed to assess the 
recognition of self glycolipids by MDSC after potential oxidation by NO and other 
reactive oxygen species, or in combination of other stimuli, mimicking conditions 
found in inflammation.   
 
To examine if genetic material lost from dying cells or from viruses may activate 
MDSC, we tested the effect of CpG, dsDNA, and poly (I:C), dsRNA on MDSC’s 
production of NO through Griess reaction, but neither of these activated MDSC.  This 
finding is contradictory of a previous report’s claims of poly (I:C) inducing activation 
of BM-MDSC (Liu et al., 2011).  This may be due to the signalling mechanism.  It 
has been described that stimulation with pathogen stimuli, from bacteria or fungi, 
signal through MyD88/TLR4, whereas it has been shown that dsRNA signals through 
TLR3 can act via a TRIF-dependent, MyD88-independent mechanism (Abbas AK, 
2010). We investigated whether signals from our bacterial and fungal pathogens 
require MyD88 for activation, as some Th17-like stimuli can also signal through 
dectin-1 to induce Th17 polarization by DC.  MDSC lacking the MyD88 adaptor 
protein cannot produce NO from any of the stimuli, indicating the role of MyD88 
signalling is essential for the activation of NO.  The role of MyD88 has been observed 
in MDSC from mice with sepsis (Delano et al., 2007).   Interestingly, CpG has been 
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reported to suppress the generation of MDSC by causing their further differentiation 
(Zoglmeier et al., 2011).  
 
It has also been noticed that MDSC demonstrate a synergistic effect upon a combined 
stimulation with LPS/IFN-g (Greifenberg et al., 2009).  As we were interested in 
understanding MDSC during Th1 and Th17 conditions, we investigated the role of IL-
17 in MDSC activation.  It has been reported that MDSC have the ability to produce 
TGF-b (Li et al., 2009; Terabe et al., 2003), which may present an interesting role of 
MDSC in regulating Th17.  Griess reagent was employed to analyze if MDSC can be 
activated specifically by IL-17 and if this activation could act in concert with other 
stimuli to synergistically boost the NO production in the same manner as IFN-g.  
Similarly to the inability of IL-17 to influence macrophage NO production (Jovanovic 
et al., 1998), BM-IMC did not secrete any NO after stimulation with IL-17, nor did 
IL-17 boost the amount of NO produced by other stimuli. Interestingly, this boost 
seems to be restricted to IFN-g.  It has been reviewed in macrophages that the synergy 
occurs between TLR signalling (Schroder et al., 2006), resulting in IFN-g signalling 
through IFN-gR resulting in STAT-1 translocation and NF-kB activation.  The overall 
result of this synergy results in increased macrophage NO and other effector functions.  
IFN-g and TLR seem to influence the expression of each other’s receptors, as IFN-gR 
signalling changes the expression of TLR2 and TLR4 (Schroder et al., 2006). To 
analyze this signalling we used IFN-gR1 deficient mice, in the presence of bacteria 
and fungi components.  We observed a reduction in NO production in this system. 
Colleagues have assessed the role of IFN-gR1 in MDSC ability to suppress T cell 
responses and have found that MDSC lacking IFN-gR1 do not suppress as well as 
those with IFN-gR expression (Ribechini, unpublished).  Interferon regulatory factor-
1 (IRF-1) plays a major role in regulating IFN-gR signalling further downstream, such 
as induction of iNOS (Kamijo et al., 1994), IL-1b (Tamura et al., 1995), and type I 
IFN (Miyamoto et al., 1988).   
 
IRF-1, a downstream element of IFN-g signaling, has been notably associated with 
susceptibility to EAE (Buch et al., 2003; Tada et al., 1997) and progression of MS 
(Fortunato et al., 2008). With the use of IRF-1 knockout MDSC, we further showed 
that IRF-1 signalling only plays a partial role in production of NO within MDSC.  
This partial decrease was seen by knockdown in only one allele and was not further 
decreased by the full knockout.  This differs from the common result seen in literature 
based on other cell types.  The ability of IRF-1 knockout mice upon LPS/IFN-g 
stimulation to produce iNOS has been reported by various groups (Kamijo et al., 
1994; Martin et al., 1994; Salkowski et al., 1996).  Corresponding most likely to this 
small reduction in iNOS, IRF-1 only slightly reduced the ability of MSDC to suppress 
T cells in a suppressor assay (Ribechini, unpublished).  IRF-1 has been shown to play 
a role in IFN-g mediated regulation and constitutive expression of B7-H1 (Lee et al., 
2006). Indications suggests that other IRF molecules, such as interferon consensus 
sequence binging protein / interferon regulatory factor-8, are involved in signalling 
through CSF, IFN-g and TLRs, and modulating an important transcription factor in 
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myeloid cells (Nerlov and Graf, 1998), PU.1, IRF-8 has been shown to have 
importance in MDSC activation (Stewart et al., 2009), as IRF-8 and PU.1 have been 
reported to be induce Arg-1 activity.  Therefore, the role of interferons and their 
regulation is crucial to the development and effector functions of MDSC.    
 
5.4 IFN-b treatment does not directly influence BM-IMC in vitro. 
As IFN-g and its regulation plays a major role in MDSC, we wanted to assess another 
interferon family member, but from the Type I interferons, IFN-beta.  Type I 
interferons play a major role in regulation of the immune system, but unlike Type II 
interferons, namely IFN-g, the type I IFN, IFN-a and IFN-b, are contributed by innate 
immune cells, predominantly plasmacytoid DC (Abbas AK, 2010).  It has been shown 
that IFN-b and IFN-g play opposing roles in immune activation and their signalling 
has been discovered to negatively regulate each other (Rayamajhi et al., 2010).  
Alternatively, it has been suggested low levels of type I IFN are required to sustain 
IFN-g signaling (Nguyen et al., 2000; Takaoka et al., 2000).  As IFN-g boosts NO 
production in MDSC, assessment of IFN-b, a cytokine given for treatment of MS 
patients, on MDSC activation and function was performed.  IFN-b was found to 
neither activate nor suppress the activation of MDSC NO production.  Nor does it 
influence the ability to suppress by the addition of exogenous IFN-b-1a and IFN-b-1b, 
and other factors which normally lead to increased IFN-b production (such as poly 
(I:C)), into the suppression assay, or influence suppression in BM-IMC which lack 
IFN-aR.  This result differs from reports stating the presence of autocrine IFN-b 
release peritoneal macrophages from their suppressive phenotype in vitro (Hamilton 
et al., 2010).  This effect was interestingly noted to correspond with activation by 
TRIF, but not MyD88 signalling (Hamilton et al., 2010).  It has been also reported 
through the use of IFN-aR blocking antibodies that IFN-aR is required for Ly-6Chi, 
but not Ly-6Cint. differentiation from BM (Seo et al., 2011), but as their culture 
conditions did not include GM-CSF this indicates GM-CSF may negate IFN-a/b 
required signalling in vitro. Therefore, we conclude that the IFN-b therapy does not 
directly influence BM-MDSC in vitro.  Recently, MDSC indirect suppression of type 
I and II interferons was demonstrated.  MDSC reduce the production of IFN-g and 
IFN-b by other immune cells at the activation level, i.e., though nitrosylation of 
STAT-1 in cancer (Mundy-Bosse et al., 2011) leading to less activation and therefore 
less effector cytokine function.  The treatment of MS by a potential combination 
therapy of IFN-b and MDSC cellular therapy may be attractive as the cytokine IFN-b 
itself has not been discussed as being altered, although this has never been addressed. 
The induction of type I IFNs, lack direct influence on MDSC, may influence other 
members of the immune system, such as enhancing function and quantity of Tregs (de 
Andres et al., 2007) and/or negatively regulating Th17 (Guo et al., 2008).  Therefore 
administration of a combination therapy including IFN-b and MDSC may provide 
better outcomes in overcoming autoimmunity. 
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5.5 Migration of BM-MDSC 
Knowledge of localization of cells given as cellular therapy is required to assess 
mechanisms in vivo. To understand the cell trafficking, BLI was employed to observe 
in vivo kinetics of the intraveneously injected BM-IMC.  Upon i.v. injection, BM-
IMC seem to spread over the mouse, but slowly accumulated in the spleen, where 
peak accumulation was on day 4.  The cell numbers in the spleen subsequently 
decreased, we speculate by possibly either death or recirculation.  This homing 
process reflects current theory described by Swirski et al., as they describe the spleen 
as a reserviour for monocytes (Swirski et al., 2009).  To understand where in the 
spleen the cells were located, we then analyzed the spleen for our labeled BM-IMC.  
Interestingly, we located them back in the outside the white pulp.  iNOS+ monocytes 
have been reported during Listeria infection to interact with memory CD8+ T cells in 
the red pulp (Bajenoff et al., 2010).  
 
To answer where IMC migrate/home to mediate their suppression, BM-IMC were 
administered during low grade EAE. BM-IMC migrated similarly to the spleen when 
administered into a mouse displaying EAE symptoms and steady-state, but also to the 
site of inflammation (CFA/MOG injection site) and the draining lymphnodes during 
times of inflammation. It had been described that in migration of endogenous cells 
during tumors high amounts of MDSC accumulate in the liver, spleen, blood, BM, 
and tumor site (Ilkovitch and Lopez, 2009).  As our test was not sensitive enough to 
see the cells within the blood, this data corresponds nicely with our results displaying 
the MDSC in the spleen, and inflammation site.  Using a model of using sponges as 
an artificial site of inflammation, it was reported endogenous MDSC migrate to the 
site of inflammation (Ribechini et al unpublished), where it was shown NO was 
produced (Witte and Barbul, 2002).  Interestingly, we had seen additional signal of 
our cells within the lymph nodes, which had been seen previously in our lab within 
the endogenous population, but this increase was so small, it had previously been 
discounted (Ribechini, unpublished).  O’Connor et al. have described similar 
localization of IMC during adjuvant immunotherapy, which induces further 
recruitment of T cells to the lymph nodes rather than the brain whereby inducing 
protection.  Interestingly, Zhu et al. has published the observation of IMC in the brain 
by using the CD45.1 marker suggesting the cells exert their ability to suppress in the 
brain itself (Zhu et al., 2011).  The recruitment to the spleen may be similar to that of 
the endogenous CD11b population, which also migrates to the spleen during EAE 
(Zhu et al., 2007).  This recruitment and accumulation of endogenous CD11b cells to 
the spleen has been observed by Mtb (Billiau and Matthys, 2001), thereby explaining 
the observed splenomegaly (Wang et al., 2010).  This increased CD11b population 
has been observed ex vivo to be suppressive, providing an indication that the CD11b 
population may play a role in suppression of the disease (Zhu et al., 2007).  
 
From these observations, we attempted to use fluorescent labeling to look at the BM-
IMC injected cells ex vivo from the spleen to characterize their expression.  
Unfortunately, much difficulty was encountered during the process of recovering the 
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BM-IMC from the spleen.  Many conventional methods were attempted to recover 
them for analysis by flow cytometry, but these proved unsuccessful.  Finally, after 
another trial, we noticed a “blob” of collagenous-like material that would always 
appear in the cell suspension.  We plan to use collagenase staining on paraffin 
sections to see if our cells colocalize with these collagen fibers within the spleen.   
Interestingly, it has been described that Arg-1 end product, proline, regulates 
proliferation and collagen deposition during asthma, cancer, parasite infection as part 
of the wound healing response (Das et al., 2010).  Also, NO has been described in 
positively regulating collagen formation, as well as having roles in cell proliferation, 
and wound contraction (Witte and Barbul, 2002).  This mass turned out to contain our 
cells, as they could be observed by microscopy. After several attempts to digest the 
“blob” using collagenase III and DNase I, we still could not isolate our cells from this 
mass.  More experiments must be performed to determine the optimal method to 
retrieve these cells, possibly using other methods of RBC lysis in combination with 
digestion of other matrix proteins.  It has been observed in humans that CD14+ 
monocytes can differentiate into endothelial cells through the presence of adiponectin 
(Yang et al., 2006), a molecule involved in the promotion of angiogenesis. MDSC 
surrounding the blood vessel release NO into the blood stream during tumors (Yang, 
2010).  
 
5.6 Protection by BM-IMC 
Once we established that BM-IMC protect against EAE, we then altered the protocol 
to establish the method providing the best protection. MDSC have generally a 
differentially described mode of suppression as compared to the reportedly protective 
semi-mature DC (Pletinckx et al., 2011).  The semi-mature DC induce immune 
tolerance through immune deviation by shifting the response from a Th1 response to 
either Th2 or IL-10 Tr1 responses (Menges et al., 2002).  This induces a less vigorous 
immune response therefore causing less damage within the CNS (Pletinckx et al., 
2011).  In other models, MDSC on the other hand have not been observed to cause 
immune deviation to date, but rather induce suppressive mechanisms which cause the 
T cells to be dysfunctional (Gabrilovich et al., 2012).  Interestingly, MDSC have been 
shown to induce Tregs (Gabrilovich et al., 2012). We injected BM-IMC at a D-3, and 
found these mice were still able to suppress EAE. Ioannou et al. published that BM-
IMC when injected post EAE induction utilitzed the B7-H1 and PD-1 interaction to 
mediated protection by the PMN-MDSC (Ioannou et al., 2012) subset. Attempts 
performed by us and previous members in our lab could not find a protective effect 
with BM-IMC post-EAE induction.  This discrepancy observed may be attributed to 
possibly different sources of BM-IMC as they are a heterogenous population.  We 
have concluded injection of BM-IMC could only be given preventively to provide 
protection.  To determine whether the cells must be activated in vivo or could be pre-
activated to provide better protection we injected BM-MDSC matured with LPS/IFN-
g instead of BM-IMC.  We have shown that injection of activated BM-MDSC, rather 
than BM-IMC, partially blocks the ability to suppress. Curdlan-activated BM-IMC 
injection into mice could not be attempted, as curdlan particles are too large.  We 
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postulate the activation of BM-IMC into BM-MDSC causes the release of NO 
possibly before they reach the necessary location, or maybe even before injection, but 
this must be further investigated.  Also, it has not been investigated whether these 
cells home to the similar place or interact with the same cells; this is however beyond 
the scope of this thesis.  
 
To determine if the MDSC can suppress the pathologic causing cytokines IFN-g and 
IL-17 in vivo, we assessed the infiltrates within the CNS of EAE mice receiving pre-
treatment of BM-IMC.  Overall, there was no statistically significant change in the 
cytokines.  In the spleen, very low amounts of IFN-g and IL-17 were detected even in 
control EAE mice, this increased in the mice treated with BM-IMC although this 
change was not significant.  No significant change in cytokine production between the 
groups was observed in the CNS upon restimulation either.   We were confused by 
this finding, because given a reduction in the clinical score, one would not expect to 
find similar amounts of cytokines which are thought to be involved in the disease 
progression.  As we hypothesized IFN-g, as had been previously shown to be 
inhibited in several in vivo models, but also IL-17, as it was reported to be specifically 
inhibited by NO (Nath et al., 2010), would have been suppressed in BM-IMC 
protected EAE mice.  When re-evaluating our restimulation for cytokine analysis, we 
found PMA/Iono, which stimulate the cells through calcium influx (ionomycin) and 
protein kinase C activation (PMA), without the use of the TCR (Weiss et al., 1986), 
may not be the best choice for this assay.  The TCR has been discussed as a possible 
place of nitrosylation by NO released from MDSC (Gabrilovich et al., 2012).  
Therefore, future experiments should assess the cytokine production using other 
stimuli, for example a specific restimulation using MOG peptide.  Interestingly, others 
have found a reduction in CNS pathological cytokines upon application of BM-IMC 
after specific restimulation with MOG using CD4+ T cell transgenic mice, 2D2 (Zhu 
et al., 2011).   
 
It has been shown in brain tissue that upregulation of B7-H1 decreases the CD4 T cell 
production of IL-17, IFN-g, and IL-10 (Duncan and Miller, 2011), therefore increased 
B7-H1 can suppress clinical severity in Theiler’s virus model of MS.  To address the 
aim of investigating the role of different mechanisms of suppression we first went to a 
mechanism of tolerance described by Wherry et al. (Freeman et al., 2006), termed 
“exhaustion.”  As MS is a chronic disease, and MDSC are also found in chronic 
inflammatory conditions, this mechanism of B7-H1 and PD-1 interaction may be 
utilitized by MDSC to be suppressive.  The role of B7-H1 interaction with PD-1 on 
memory T cells was assessed in vitro. Our findings displayed that B7-H1 reduced the 
ability of MDSC to suppress memory T cells.  Expression of B7-H1 on endogenous 
and in vitro MDSC was noted upon restimulation, suggesting although the 
endogenous MDSC have the ability to suppress, it might be a numbers game.  It has 
been shown that MDSC appear in the peripherial blood peaking around day 6 - 9 and 
in spleen peaking on day 21 in CFA treated mice (Wang et al., 2010), suggesting the 
BM-IMC delivered at the earlier timepoints gives the mouse the protection.  In vivo, 
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we found different results. The expression of B7-H1 upon the injected IMC was not 
required for suppression of the disease.  PD-1 on recipient mice, however did seem to 
play a role in suppression of EAE by MDSC.  There are several factors contributing to 
these differential results.  We believe that this interaction between B7-H1 and PD-1 
occurs during chronic situations (Freeman et al., 2006).  The timing of our MDSC 
injection is before the induction and onset of the disease, and therefore it is possible 
that the cells may die off before they can suppress at these late timepoints as rapid 
turn over of MDSC has been reported.  This NO production may influence other cells 
inducing suppression, or may activate others to suppress through PD-1.  Another 
explanation could be the cells use another ligand besides B7-H1 to interact with PD-1, 
but as B7-H2 is not upregulated on the BM-MDSC after stimulation, and other 
ligands have not been described, we believe this is unlikely.  Proof supporting the 
timing possibility has been reported showing the suppression of EAE by B7-H1 
expressed on PMN-MDSC upon MDSC administeration after EAE induction 
(Ioannou et al., 2012).  We however do not see this protection, as BM-IMC injected 
post-EAE induction does not cause protection in our hands.  Therefore, these 
experiments need to be repeated to confirm this finding, or to see if other factors such 
as their source of MDSC, may contribute to the differences seen.  Interestingly, there 
are some reports supporting the role of PD-1 within the CNS, as not being related to 
the exhausted phenotype, but a method employed to mediate tissue damage 
(Sadagopal et al., 2010).  
 
 
5.7 BM-IMC may induce proliferative effects rather than suppressive effects 
in vivo 
Upon examining the spleens of receiving BM-IMC, compared to untreated mice, we 
saw an increase of spleen size.  Interestingly, upon one of our attempts to understand 
if the MDSC suppress specifically by forcing the interaction of MDSC MHC with the 
TCR of T cells using SEB, we found that untreated “resting” T cells when forced to 
interact with MDSC proliferated slightly.  Therefore, we thought this could be a 
similar situation, and that during steady-state, the injection of these cells may cause 
slight proliferation of surrounding cells.  To examine this, we injected cells, waited 4 
days, and then assessed the induction of proliferatation ex vivo by labeling the 
splenocytes with CFSE and analyzing the dilution.  Splenocytes from mice pre-
injected with BM-IMC had an increased proliferation in many cell types, including T 
cells, B cells, and myeloid cells.  Previous reports support endogenous Gr1+ cells in 
the spleen priming of B cells, as their interaction within the red pulp has been seen in 
Alum injected mice (Jordan et al., 2004).  This proliferation in CD4 cells, when 
examined in closer detail showed increased proliferation of Tregs, as compared to 
Teff cells.  The induction of Tregs by MDSC has been shown, but these studies have 
been in models of tumor and inflammation (Huang et al., 2006) (Serafini et al., 2008).  
Interestingly, others have discussed mast cells can induce MDSC to secrete IL-17 
under certain conditions leading to the recruitment and increased suppressive capacity 
of Tregs (Yang et al., 2010).  Further studies will have to be performed to analyze if 
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there is an increased recruitment in addition to proliferative response, although current 
data suggestions this may not be the case (Yang et al., 2010).   
 
To assess whether this proliferation is regulated by PD-1 interaction with B7-H1, we 
analyzed spleens from PD-1-/- mice receiving the preinjection of MDSC.  Interestingly, 
spleens from PD-1-/- mice receiving BM-MDSC have no increase of spleen cellularity.  
Therefore, this proliferation may be induced by interaction of MDSC with PD-1 
directly, or indirectly.  It has been reported to induce proliferation rather than 
suppression under certain situations, by utilizing antibodies for PD-1, but not upon 
interaction with B7-H1 (del Rio et al., 2005). To confirm this data we also tested 
spleens from mice receiving BM-IMC from B7-H1-/- and WT mice injected post EAE 
induction. The spleens lacking the expression of B7-H1 did show an increase in 
splenic cellularity similar to that of WT as compared to untreated EAE controls, 
implying the spleen cellularity does not relate to the cellular interaction of splenic 
cells with B7-H1 on MDSC, nor is this increase spleen cellularity the complete reason 
for this suppressive function as mice given BM-IMC post EAE injection are not 
protected.  These results suggest several possibilities in the mechanisms which 
injected BM-IMC employ; BM-IMC may prime the spleen before EAE induction, 
BM-IMC may interact with different cell types during steady-state as compared to 
inflammatory conditions, BM-IMC may locate in different areas of the spleen, or need 
activation signals in vivo which are induced by the EAE to employ their suppressive 
capacity. 
 
Our lab has already previously described the importance of two signals for the 
activation of MDSC when using LPS/IFN-g.  These two signals are IFN-g signalling 
through IFN-gR and LPS signalling through TLR4 (Greifenberg et al., 2009).  To 
understand if BM-IMC must be activated to induce this proliferation, we plan to inject 
BM-IMC from IFN-gR1-/-, iNOS-/-, and WT mice, induce EAE and assess the spleens 
for increased cellularity and proliferation capacity.  We found no differences between 
the BM-IMC groups, displaying the possibility that these cells do not differentiate 
into MDSC with suppressive function upon injection, therefore not utilizing the 
effector machinery for suppression.  As the mice given post EAE induction injection 
has similar spleen size increases, this assessment of the functionality requirement 
needs to be further elucidated.  We are currently collaborating to examine this role of 
iNOS functionality in the injected BM-IMC on the protection associated with EAE 
mice. 
 
This thesis provides insight into the ability of MDSC as a preventive cellular therapy 
to suppress the severity of EAE.  It also demonstrates where these cells would home, 
i.e., the spleen, and gives several possibilities for the mechanisms which the cells 
might utilize in order to suppress, i.e., NO and Arg-1 and possibly modulating effects 
through PD-1, but not B7-H1.   
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7 GSLS Thesis Guidelines  
 
Mandatory Elements  
LAB MEETING = GROUP SEMINAR 
Required: usually 1h/ week, organized by the research group or the graduate training 
group: 
• Institute of Immunology Seminars (Every Tuesday) 
• Lab Meeting (Every Friday) 
LITERATURE SEMINAR = JOURNAL CLUB 
Required: usually 1h/ week, organized by the research group or the graduate training 
group 
• Institute of Immunology Literature Seminars (Every Wednesday) 
RESEARCH TRAINING GROUP SEMINAR (Jour Fixe) 
Required: usually once or twice per month 
• Immunomodulation (Every Thursday)  
OTHER SEMINARS/MEETINGS 
• SFB581 Seminars (Some Thursdays) 
• Immunology and Virology Seminars (Monday nights) 
MEETINGS / SYMPOSIA  
Required: 3 International events with scientific participation within 3 years 
• Lugano, Switzerland, 2010 (DC and Vaccines  Meeting) 
• Brussels, Belgium, 2011 (Dendritic Cell and Macrophage Society Meeting) 
• Wuerzburg, Germany, 2011 (GSLS Graduate School Meeting)  
Non-International events attended 
• 2009 Marburg Meeting 
• 2011 Transregio 52 Meeting 
SCIENTIFIC PUBLICATIONS 
Ribechini E, Greifenberg V, Sandwick S, Lutz MB. (2010) Subsets, expansion and activation 
of myeloid-derived suppressor cells Med Microbiol Immunol. 199(84):273-281. (Review) 
 
RETREAT / SUMMER SCHOOL (one per year) e.g. organized by the research 
group, the research training group or the doctoral students Retreat: “period of group 
withdrawal under a supervisor” (3-4 days) Summer School: “academic session 
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during the summer, for remedial or supplementary study” (1-2 weeks) 
• Immunomodulation Retreat 2010 Kloster Schontal 
• Immunomodulation Retreat 2011, Bad Nereheim 
SCIENTIFIC COURSE / SEMINAR / LECTURES (one per year) organized by 
the graduate training group, GSLS, doctoral students or offered externally (e.g. 
method course, statistics, clinical medicine, “Hottest Life Science in Town”) 
• 2011 Abbas Book Seminar (Hosted by Immunomodulation) 
• 2009 Animal Training Course 
• 2009, 2010 German Language Courses 
Electives (at least one of the following per year)  
TRANSFERABLE SKILLS COURSE / SEMINAR / WORKSHOP  
e.g. poster presentation, scientific writing 
• 2010 Statistics Course (3 parts) 
• 2011 Writing for Publication 
• 2011 Grant Writing 
CONTRIBUTION TO ACTIVITIES OF THE GSLS 
e.g. peer mentor, DSC, teaching activities, organisation of events 
• 2011 Assisted in Manfred Lutz section of Student Practical Course  
WORKING STAY 
e.g. scientific fieldwork, laboratory training, usually outside University of Würzburg 
• Transregio 52 collaboration with Dr. Ari Waisman, Mainz, learned EAE CNS 
isolation techniques. 
• Mini-project with Anoop Chandran, Dr. Jörg Wischhusen, Frauenklinik, 
Würzburg, learned miRNA isolation, poly-adenylation, RT-PCR. 
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8 Curriculum Vitae 
 
Sarah Jane Sandwick
 
 
 
ACADEMIC PREPARATION:
PhD, Manfred B. Lutz Lab, Universität Würzburg, May 2009 – July 2012 
  Major: Immunology
 
MS, Johns Hopkins University with a Thesis, 2009 
  Major: Biotechnology
  
BS, University of Southern Maine, 2006 (GPA: 3.17) 
Double Major: Biology (emphasis in Biotechnology) and Political Science  
Minor: Biochemistry  

RESEARCH SKILLS: 
General Laboratory Skills:  Sample handling, database management, pipetting, and 
preparation of various solutions, preparations of dilution series, use of pH meter, balance, 
centrifuge, spectramax, flow cytometers, in vivo/ex vivo bioluminescence imaging, western 
blotting, ELISA, plaque assay, cell culture including primary cell cultures such as immature 
myeloid cells, dendritic cells, macrophages, and T cells, surface and intracellular cell staining, 
CBA, proliferation assays, histology (immuno-fluorescence), isolation of RNA, micro-RNA 
screenings, BSL2/BSL3/BSL4 tissue culture, and analysis of data. 
 
Animal work:   
Mouse work-  
General: Blood collection, splenectomies, euthanasia, perfusions 
Injections: IV, IP, IM, SC, oral gavage 
Dissections for various organs: including liver, pancreas, spleen, bone marrow, spinal chord, 
brain, lungs, and lymph nodes  
 
Chicken work-  
Dissections:  spinal motor neuron and forebrain dissections 
 
Vaccines received: 
Smallpox, Tularemia, Anthrax, Venezualan Equine Encephalitis, Rift Valley Fever Virus, 
Yellow Fever 
 
PROFESSIONAL EXPERIENCE: 
Universität Würzburg *, May 2009 - Present 
Sponsor:  SFB-581 
Supervisor:  Dr. Manfred Lutz 
Committee Members: Dr. Stephan Kissler, Dr. Rudolf Martini, Dr. Andreas Beilhack 
 
Projects: To understand the role of myeloid derived suppressor cells (MDSC) in autoimmune 
diseases and infection.  To analyze factors involved in MDSC activation and suppressive 
mechanisms.  Understanding the migration patterns of all subsets under different conditions.  
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In vivo bioluminescence imaging, Experimental autoimmune encephalomyelitis, asthma 
models, flow cytometry, immunohistochemistry, cytospins, proliferation assays, ELISAs, 
intracellular cytokine stainings, literature and progress report seminars, participation in 
Immunomodulation gradutate program, assistant in student practical course (2011). 
 
 
United States Army Medical Research Institute for Infectious Disease (USAMRIID) **, 
December 2006 – May 2009 
Sponsor:  Oak Ridge Institute for Science and Education (ORISE) 
PI:  Dr. Sina Bavari 
 
Projects: (divided into individual mentor’s projects) 
Dr. Steven Bradfute- Thesis work for MS.  Work in BSL4 with T cell epitope mapping of 
Ebola virus proteins, including mostly ICC and Flow cytometry. 
Dr. Mansour Mohamadzadeh- Lactobacillus acidophilus studies with dendritic cells, includes 
Flow cytometry, mouse studies, RNA isolation, ELISA, MTT neutralization assay, T cell 
proliferation assays, immunohistology.  
Dr. Sheli Radoshitzky- Cowpox and Rift Valley Fever Virus studies with transfected cells 
Dr. Gordon Ruthel- Bontulinum studies with chicken primary cultures 
Dr. Travis Warren- Small molecule therapeutics against Rift Valley Fever Virus, Cowpox 
(BSL3 agents), mostly propagation of virus stocks, plaque assays. 
 
- Flow cytometry, mouse work.  Rotating lab manager (November-December 2008), 
organized laboratory team building day 2008, mentorship of fellow personnel in BSL3. 
 
IDEXX Laboratories, February 2006 – December 2006 
Mycobacterium paratuberculosis (Mpt) ELISA group 
Head Supervisor:  Dr. Lisa Estey 
Lab Supervisors: Jill Kerrick, Dr. Jay Jayarama  
Project: Development of ELISA assays to improve a current kit that is on the market which 
detects Mycobacterium paratuberculosis in cow herds. 
 
-ELISA optimization, databasing of samples. 
 
National Aeronautics and Space Administration (NASA) Lyndon B. Johnson Space Center, 
June 1, 2005 – August 15, 2005 
Sponsor:  Maine Space Consortium Grant 
PI: Dr. Steve R. Gonda,  
Mentors: Racheal Casey and Kamal Emami 
Project: Big Blue Mutagenesis Assay  
 
-  3-dimensional cell culture, comparison of agars, Big Blue mutagenesis assay, which 
includes DNA extraction, transpacking, and cII, presentations, attending seminar 
presentations.  I have done several presentations stemming from this research: An exit 
presentation, high school presentations, oral presentation at the MSCG annual meeting. 
 
Wise Laboratory of Environmental and Genetic Toxicology***, September 2003 – May 2006 
Sponsor:  unsponsored and NASA grant 
PI/Mentor:  Dr. John Pierce Wise Sr.,  
Mentor: Amie Holmes 
Project: Comparative toxicology studies on human lung cells and bowhead lung cells  
 
-  Cytotoxicity, Chromosome Damage, Clonal Expansion, Cell Culture, Media Preparation, 
Chemical/Metal Preparation, journal presentations, internal presentations, and external 
SANDWICK DOCTORAL THESIS, JUNE 2012! CURRICULUM 
VITAE 
 
P a g e | 98  
 
presentations. Research funding awarded from SURF Fellowship (through USM) –Summer 
2004 and NASA –Fall/Spring Semester 2004.  I won second place at the Northeastern Society 
of Toxicology Symposium on a poster presentation on this research. 
 
 
* This research is currently supported by the SFB-581. 
* This research was supported in part by an appointment to the Postgraduate Research 
Participation Program at the US Army Medical Research and Materiel Command 
administered by the Oak Ridge Institute for Science and Education through an interagency 
agreement between the US Department of Energy and the USAMRMC.  
 
** This research was supported by the NASA Grant (Fall 2004 - Feb 2005), while research 
done during the Summer of 2004 was supported by the Serf Fellowship (USM Grant). 
 
GRANTS RECEIVED: 
Fall 2004 - Feb 2005 NASA Grant 
Summer 2004 Serf Fellowship (USM Grant)  
December 2006-December 2008 USAMRIID Sponsor: This research was supported in part by 
an appointment to the Postgraduate Research Participation Program at the US Army Medical 
Research and Materiel Command administered by the Oak Ridge Institute for Science and 
Education through an interagency agreement between the US Department of Energy and the 
USAMRMC.  
 
PUBLICATIONS:  
Sandwick SJ, Bradfute S, Bavari S. (2011) J. Virol. (in preparation). 
 
Ruthel G, Burnett JC, Nuss JE, Wanner LM, Tressler LE, Torres-Melendez E, Sarah J. 
Sandwick, Retterer CJ and Bavari S. (2011) Post-Intoxication Inhibition of Botulinum 
Neurotoxin Serotype A within Neurons by Small-Molecule, Non-Peptidic Inhibitors. Toxins. 
3:207-217. 
 
Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K, Kuhn JH, Sandwick S, 
Ruthel G, Kota K, Boltz D, Warren T, Kranzusch PJ, Whelan SP, Bavari S. (2010) Infectious 
Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol. 84(20):10569-80.  
 
Ribechini E, Greifenberg V, Sandwick S, Lutz MB. (2010) Subsets, expansion and activation 
of myeloid-derived suppressor cells Med Microbiol Immunol. 199:273-281. (Review) 
 
Mohamadzadeh M, Duong T, Sandwick SJ, Hoover T, Klaenhammer TR. (2009) Dendritic 
cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus 
protects mice from lethal challenge Proc Natl Acad Sci U S A. 106(11):4331-4336. 
 
Holmes, A.L., Wise, S. S., Sandwick, S.J., Lingle, W.L., Negron, V.C., Thompson W.D., and 
Wise, Sr., J.P. (2006) Chronic Exposure to Lead Chromate Causes Centrosome Abnormalities 
and Aneuploidy in Human Lung Cells. Cancer Research 66(8):4041-4048. 
 
Holmes, A.L., Wise, S. S., Sandwick, S.J., and Wise, Sr., J.P. (2006) The Clastogenic Effects 
of Chronic Exposure to Particulate and Soluble Cr(VI) in Human Lung Cells. Mutation 
Research, 610(1-2): 8-13. 
 
Wise, S.S., Holmes, A.L., Moreland, J.A., Xie, H., Sandwick, S.J., Stackpole, M.M., 
Fomchenko, E., Teufack, S., May, Jr., A.J., Katsifis, S.P., and Wise, Sr., J.P. (2005) Human 
Lung Cell Growth Is Not Stimulated by Lead Ions after Lead Chromate-Induced 
Genotoxicity. Molecular and Cellular Biochemistry 279 (1-2):75-84. 
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PAPERS PRESENTED AT CONFERENCES: 
Moreland, J.A., Teufack, S., Sandwick, S., Dufour, J-F., Wise, S.S., Holmes, A.L., 
Ketterer, M.E., Hartsock, W.J., Fomchenko, E., Katsifis, S.P., and Wise, Sr., J.P. 
Particulate Hexavalent Chromium-Induced Cell Cycle Arrest Is Mediated by Cr Ions. 
Proceedings of the Northeast Society of Toxicology (NESOT) Annual Meeting, 
November 2003. 
 
Moreland, J.A., Teufack, S., Sandwick, S., Dufour, J-F., Wise, S.S., Holmes, A.L., 
Ketterer, M.E., Hartsock, W.J., Fomchenko, E., Katsifis, S.P. and Wise, Sr., J.P. Lead 
Chromate (LC) Induces Cell Cycle Arrest in WTHBF-6 Cells, However Lead Alone 
Is Mitogenic. Toxicological Sciences 67(S): 270, 2004. 
 
Wise, S.S., Holmes, A.L., Xie, H., Gordon, N., Moreland, J.A., Sandwick, S.J., 
Stackpole, M.M., Fomchenko, E., Teufack, S., May, Jr., A.J., Katsifis, S.P., 
Thompson, W.D., and Wise, Sr., J.P. Mechanisms of Particulate Chromate-Induced 
Genotoxicity. Proceedings of the 3rd Conference on Molecular Mechanisms of Metal 
Toxicity and Carcinogenesis. September 2004. 
 
Sandwick, S.J., Holmes, A.L., Wise, S.S., Gordon, N., and Wise, Sr., J.P. Lead Ions 
Disrupt Normal Mitotic Progression in Human Lung Cells after More Chronic 
Exposures to Lead Chromate. Proceedings of the Annual Meeting of the Northeast 
Chapter of the Society of Toxicology, October 2004. 
 
Holmes, A.L., Sandwick, S.J., Wise, S.S., Gordon, N., Thompson W.D., and Wise, 
Sr., J.P. Chronic Exposure to Lead Ions from Lead Chromate Interferes with Normal 
Mitotic Progression. Toxicological Sciences 84(S-1): 1145, 2005. 
 
Wise, S.S., Holmes, A.L., Sandwick, S.J., Gordon, N., Thompson W.D., and Wise, 
Sr., J.P. Lead Ions Interfere with Repair of Particulate Chromate-induced 
Chromosome Aberrations Resulting in Prolonged Chromosome Instability in Human 
Lung Cells. Proceedings of the American Association for Cancer Research 46:3043, 
2005. 
 
Wise, S.S., Holmes, A.L., Sandwick, S.J., and Wise, Sr., J.P. Chronic Exposure to 
Lead Chromate Induces Premature Anaphase and Inhibits Repair of Chromosome 
Damage in Human Lung Cells. Proceeding of the American Thoracic Society, 2: 
A744, 2005. 
 
Holmes, A.L., Wise, S.S., Sandwick, S.J., Lingle, W.L., Negron, V.C., and Wise, Sr., 
J.P. Chronic Exposure to Lead Chromate Causes Centrosome Abnormalities and 
Aneuploidy in Human Lung Cells. Proceedings of the Biennial Meeting of the 
Chromium and Human Health Workshop, August 2005. 
 
Wise, S.S., Holmes, A.L., Sandwick, S.J., and Wise, Sr., J.P. Lead Chromate-Induced 
Centromeric Abnormalities in Human Lung Cells. Proceedings of the Biennial 
Meeting of the Chromium and Human Health Workshop, August 2005. 
 
Holmes, A.L., Wise, S.S., Sandwick, S.J., Lingle, W.L., Negron, V.C., and Wise, Sr., 
J.P. Chronic Exposure to Lead Chromate Causes Centrosome Amplification and 
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Aneuploidy in Human Lung Cells. Toxicological Sciences 90: 519, 2006. 
 
Holmes, A.L., Wise, S.S., Sandwick, S.J., Lingle, W.L., Negron, V.C., and Wise, Sr., 
J.P. Lead Chromate-Induced Chromosome Instability is Caused by Centrosome 
Amplification in Human Lung Cells. Proceedings of the American Association for 
Cancer Research 47: 1088, 2006. 
 
PAPERS PRESENTED AT LOCAL CONFERENCES:  
Sandwick, S., Wise, S.S., Holmes, A.L., and Wise, Sr., J.P. The Effect of Exposure 
Time on Lead Chromate-Induced Cytotoxicity in Human Lung Cells. Proceedings of 
University of Southern Maine's Student Research Day 20, 2004. 
 
Moreland, J.A., Teufack, S., Sandwick, S., Dufour, J-F., Wise, S.S., Holmes, A.L., 
Ketterer, M.E., Hartsock, W.J., Fomchenko, E., Katsifis, S.P. and Wise, Sr., J.P. Lead 
is Mitogenic to WTHBF-6 cells, but Lead Chromate (LC) Induces Cell Cycle Arrest. 
Proceedings of University of Southern Maine's Student Research Day 45, 2004. 
 
Sandwick, S., Holmes, A.L., Wise, S.S., and Wise, Sr., J.P. Comparison of Human 
and Bowhead Lung Cells through Cytotoxicity, Metal Ion Uptake, and Clastogenicity. 
Proceedings of University of Southern Maine's Student Research Day 11, 2005. 
 
Holmes, A.L., Wise, S.S., Sandwick, S.J., Lingle, W.L., Negron, V.C., and Wise, Sr., 
J.P. Lead Chromate-Induced Chromosome Instability Is Caused by Centrosome 
Amplification in Human Lung Cells. Proceedings of University of Southern Maine's 
Student Research Day 65, 2006. 
 
Sandwick, S.J., Karaczyn, A.A., and Wise, Sr., J.P. In Vitro Toxicity and Neoplastic 
Transformation of Depleted Uranium: Effects on Human Bronchial Epithelial Cells.   
Proceedings of University of Southern Maine's Student Research Day 58, 2006. 
 
 
